SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-K
Annual Report pursuant to Section 13 or 15(d)of the Securities
Exchange Act of 1934For the fiscal year ended March 31, 1999 Commission
File No. 1-9114
MYLAN LABORATORIES INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 25-1211621
(State or other jurisdiction of (IRS Employer Identification No.)
incorporation or organization)
1030 Century Building
130 Seventh Street
Pittsburgh, Pennsylvania 15222
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: 412-232-0100
Securities registered pursuant to Section 12(b) of the Act:
Name of Each Exchange
Title of Each Class on Which Registered
------------------- -------------------
Common Stock, par value $.50 per share New York Stock Exchange
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by checkmark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes...X.... No.......
Indicate by checkmark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K.[ ]
The aggregate market value of voting stock held by non-affiliates of the
registrant, computed by reference to the closing price of such stock as of June
22, 1999:
$3,180,346,246
The number of shares of Common Stock of the registrant
outstanding as of June 22, 1999:
129,153,311
Documents incorporated by reference into this Report are:
Annual Report to Shareholders for year ended
March 31, 1999... Parts I and II,
Items 1, 5-8
Proxy Statement for 1999 Annual Meeting of
Shareholders... Part III, Items 10-13
<PAGE> 2
PART I
Item 1. Business
Mylan Laboratories Inc., a Pennsylvania corporation incorporated in 1970,
and its subsidiaries (herein referred to collectively as "the Company") are
engaged in developing, licensing, manufacturing, marketing and distributing
generic and branded pharmaceutical products. References herein to fiscal 1999,
1998 and 1997 shall mean the fiscal years ended March 31, 1999, 1998 and 1997,
respectively.
The Company conducts business through its generic and branded
pharmaceutical operating segments. For fiscal 1999, the generic segment
represented approximately 88% of revenues and the branded segment represented
approximately 12% of revenues. The financial information for operating segments
required by Item 1 is hereby incorporated by reference to Note R of the Notes to
Consolidated Financial Statements in the accompanying Annual Report to
Shareholders for the year ended March 31, 1999.
Generic Segment
Through its subsidiaries, Mylan Pharmaceuticals Inc. and UDL Laboratories
Inc., acquired in fiscal 1996, the Company is recognized as a leader in the
generic pharmaceutical industry. Generic drugs are bioequivalent to their brand
name counterparts and are generally sold at prices significantly less than
branded products. Accordingly, generics provide a safe, effective and cost
efficient alternative to users of these products.
The Company attained its leadership position in the generic industry
through its ability to obtain ANDA approvals, uncompromising quality control and
devotion to customer service. To build on this position the Company has expanded
beyond its traditional solid oral dose products and now offers unit dose,
suspensions, liquids, transdermal and extended release products. The investment
in research and development and facilities to manufacture products in a variety
of delivery systems is one of the many reasons the Company is a leader in the
generic industry.
The Company has entered into strategic alliances with several
pharmaceutical companies through distribution and licensing agreements which
provide the Company with additional products to broaden the Company's product
line. In addition, the Company has entered into product development and
licensing agreements, under which the Company has obtained rights to manufacture
and distribute additional pharmaceutical products in exchange for funding of
drug development activities.
Due to the non-exclusive nature of generic products, the generic industry
is comprised of numerous competitors including manufacturers that market their
products under their own names, distributors that market products manufactured
by others, and brand name companies that market their products under both the
brand name and as the generic substitute. The non-exclusive nature thus allows
for significant price competition within the pharmaceutical industry.
Branded Segment
Pharmaceutical products initially sold on an exclusive basis are known in
the industry as proprietary or branded products. These products generally are
patent protected when introduced in the marketplace.
The Company operates its branded segment principally through its Bertek
Pharmaceutical Inc. ("Bertek") subsidiary. Bertek's three therapeutic areas of
concentration include cardiology, neurology and dermatology. The cardiology
focus is built upon Maxzide(R), Clorpres(TM) and Nitrek(R). The Maxzide(R)
products were reacquired from American Home Products Corp. ("AHP") in fiscal
1997. Since 1984, these products, which were developed and manufactured by the
Company, were marketed by AHP under a worldwide license agreement.
The Company continues to expand its branded business through internally
developed products as well as through product acquisitions. To expand its
presence in dermatology, on October 2, 1998, the Company acquired 100% of the
outstanding stock of Penederm Inc. ("Penederm"). Penederm develops and markets
through Bertek patented topical prescription products. The current product
portfolio consists of Avita(R), Mentax(R), and Acticin(R). Penederm maintains
administrative and research and development facilities in Foster City,
California.
<PAGE> 3
New Product Approvals
The Company is required to secure and maintain the U.S. Food and Drug
Administration's ("FDA") approval for the products it desires to manufacture and
market. The FDA grants such approval by approving Company submitted Abbreviated
New Drug Applications ("ANDAs") for generic drug products and New Drug
Applications ("NDAs") for branded drug products.
During fiscal 1999, the Company received ten final ANDA approvals:
Clomipramine HCl Capsules, Hydroxychloroquine Sulfate Tablets, Nystatin Oral
Suspension, Glyburide Tablets, Ranitidine Tablets, Acyclovir Tablets, Clonazepam
Tablets, Etodolac 500mg. Tablets, Albuterol Sulfate Syrup, and Extended
Phenytoin Sodium Capsules. Presently, the Company has before the FDA 35 ANDAs
pending final approval.
Also in fiscal 1999, the Company was awarded by the FDA a NDA approval for
its wound care product Sulfamylon(R). Presently, the Company has nine
Investigational New Drug (IND) applications filed with the FDA for new innovator
compounds. An IND is the result of a successful preclinical development program
and becomes part of the final NDA.
Products
The information on the Company's product line set forth on pages5-13 and 18
of the accompanying Annual Report to Shareholders for the year ended March 31,
1999 is incorporated herein by reference. For fiscal 1999, sales of the
Company's antianxiety product group accounted for approximately 22% of revenues.
During fiscal 1999, 1998 and 1997, the Company expensed $61,843,000,
$46,278,000, and $42,633,000 for research and development. The Company's
research and development efforts are conducted primarily to qualify the Company
to manufacture ethical pharmaceuticals under FDA standards and approval.
Recently this has included increased spending for innovative compounds and
transdermal delivery system technology. Typically research expenses related to
the development of innovative compounds and the filing of NDAs are significantly
higher than those associated with ANDAs. As the Company continues to develop
these products, research expenses related to their development will continue to
increase.
Customers and Marketing
The Company sells its products to proprietary and ethical pharmaceutical
wholesalers and distributors, drug store chains, drug manufacturers and public
and governmental agencies. Three customers accounted for approximately 15%, 14%,
and 11% of net sales in fiscal 1999 and 13%, 12%, and 11% of net sales in fiscal
1998. No single customer represented more than 10% of net sales in fiscal 1997.
Generic pharmaceutical products are marketed to pharmaceutical wholesalers
and distributors and certain food and drug store chains. These customers in turn
market to retailers, managed care entities, hospitals, government agencies and
consumers. Generic products involve limited public promotion. Approximately 80
employees are engaged in selling and servicing generic customers.
Branded pharmaceutical products are marketed directly to health care
professionals. Approximately 200 employees are engaged in marketing, selling and
servicing branded customers.
Competition
With respect to each of the generic products it sells, the Company believes
it is usually subject to active competition from numerous companies. The four
primary means of competition are service, product quality, FDA approval and
price. The competition experienced by the Company varies among the markets and
classes of customers. The Company has experienced additional competition from
brand-name competitors that have entered the generic pharmaceutical industry by
creating generic subsidiaries, purchasing generic companies or licensing their
products prior to or as their patents expire.
In addition to the increase in the number of competitors, the consolidation
of the Company's customers through mergers and acquisitions, along with the
emergence of large buying groups representing independent pharmacies and health
maintenance organizations, have contributed to severe price deterioration for
many of the Company's generic products. While the Company has increased unit
volume of its generic products through
<PAGE> 4
specialized marketing programs, this has not fully offset the price declines the
Company has experienced.
Severe price declines for generic products over the last several years,
along with the increased costs in bringing new generic products to market, led
the Company to an extensive evaluation of its operations. This ongoing
evaluation includes assessing the Company's relationship with key customers and
suppliers, production capacity and product level contributions. One of the key
conclusions of this evaluation was the determination that changes in the
Company's generic pricing practices were needed.
In the second half of fiscal 1998, the Company raised prices on seven
generic products. During fiscal 1999, the Company raised prices on 22 additional
products. While these price increases had a favorable impact on net earnings,
such impact, if any in the future, will be affected by many factors including
customer acceptance and the response by both existing and potential competitors
as well as by both existing and potential suppliers. The Company intends to
continue to work closely with its customers and suppliers to ensure that its
full line of generic products continues to be available as a cost effective
alternative to the innovator products.
In the branded segment, the Company faces competition from other branded
and generic pharmaceutical companies that offer products which, while having
different properties, are intended to provide similar benefits to the consumers.
Product Liability
Product liability suits by consumers represent a continuing risk to firms
in the pharmaceutical industry. The Company strives to minimize such risks by
adherence to stringent quality control procedures. Although the Company carries
insurance, it believes that no reasonable amount of insurance can fully protect
it against all such risks because of the potential liability inherent in the
business of producing pharmaceuticals for human consumption.
Raw Materials
The active chemical ingredients and other materials and supplies used in
the Company's pharmaceutical manufacturing operations are generally available
and purchased from many different foreign and domestic suppliers. However, in
some cases, the raw materials needed by the Company to manufacture
pharmaceutical products are available from a single FDA-approved supplier. Even
where more than one supplier exists, the Company may elect to list and in some
cases has only listed one supplier in its applications with the FDA. New
suppliers of the active ingredients in drugs must be approved by the FDA.
Accordingly, in the event of an interruption, any change in a supplier not
previously approved requires FDA approval, which may take several months.
In addition, recent and pending regulatory actions may make it more
difficult for the Company and other generic pharmaceutical manufacturers to
obtain commitments from foreign suppliers for raw materials prior to the
expiration of patents on branded products. The unavailability of such raw
materials could also impede the Company in its efforts to develop and obtain FDA
approval to manufacture and market new generic pharmaceutical products.
Regulation
The Company's operations are subject to regulation under the Federal Food,
Drug and Cosmetic Act, pursuant to which government standards as to "good
manufacturing practice", product content, purity, labeling, effectiveness and
record keeping (among other things) must be observed. In this regard, the FDA
has extensive regulatory powers over the activities of pharmaceutical
manufacturers including the power to seize and prohibit the sale of noncomplying
products and to halt operations of noncomplying manufacturers.
In addition to the extensive regulation the Company faces under the Federal
Food, Drug and Cosmetic Act, other regulations have also affected the generic
approval process. In June 1995, the Uruguay Round Agreements Act ("URAA") took
effect which extended patent terms pursuant to the General Agreements on Tariffs
and Trade. The extension of patent terms has delayed and is expected to continue
to delay the introduction of generic products by the Company.
While URAA has already extended patent terms, the brand companies have
further delayed the approval of new generic products by filing patent
infringement suits under the Hatch-Waxman Act. The Company upon filing
<PAGE> 5
an ANDA with the FDA must make one of five certifications with respect to
innovator patents. If the company certifies that its generic product is not
infringing or that a patent is invalid, the patentee can file suit. Brand
companies now use this certification process to prevent generic companies from
introducing competing generic products by bringing suit for alleged patent
infringement. Once a suit is filed, the FDA is prohibited from approving the
ANDA for thirty months or until the suit is litigated or settled. Along with
delaying the approval of generic products, the cost of bringing a new generic
product to market has risen substantially as the number of these suits and the
cost of defending them continues to increase. All such suits settled to date
have been on terms favorable to the Company. However, until the laws are
changed, the Company expects this type of suit will continue since it has proven
a very effective way for brand companies to delay generic competition.
The Company is subject to inspection and regulation under other federal and
state legislation relating to drugs, narcotics and alcohol. Many of its
suppliers and customers, as well as the drug industry in general, are subject to
the same or similar governmental regulations. The Company also is subject to
various federal, state, and local environmental protection laws and regulations.
Compliance with current environmental protection laws and regulations has not
had a material effect on the earnings, cash flow or competitive position of the
Company.
It is impossible for the Company to predict the extent to which its
operations will be affected under the regulations discussed above or any new
regulations which may be adopted by regulatory agencies.
Employees
The Company employs approximately 2,100 persons, approximately 1,050 of
whom serve in clerical, sales and management capacities. The remaining are
engaged in production and maintenance activities.
The production and maintenance employees at the Company's manufacturing
facilities in Morgantown, West Virginia, are represented by the Oil, Chemical
and Atomic Workers International Union (AFL-CIO) and its Local Union 8-957 under
a contract which expires April 5, 2002.
Backlog
At March 31, 1999, the uncompleted portion of the Company's backlog of
orders was approximately $7,388,000 as compared to approximately $19,899,000 at
March 31, 1998 and $10,410,000 at March 31, 1997. Because of the relatively
short lead time required in filling orders for its products, the Company does
not believe these backlog amounts bear a significant relationship to sales or
income for any full twelve-month period.
Item 2. Properties
The Company operates from various facilities in the United States and
Puerto Rico which have an aggregate of approximately 1,281,000 square feet.
Mylan Pharmaceuticals Inc. owns production, warehouse, laboratory and
office facilities in three buildings in Morgantown, West Virginia containing
473,000 square feet. Mylan Pharmaceuticals operates two distribution centers: a
166,000 square foot center in Greensboro, North Carolina which it owns and a
38,000 square foot center in Reno, Nevada which it operates under a lease
expiring in 2002. A new sales and administration facility containing
approximately 65,000 square feet and an additional production area of
approximately 11,000 square feet are currently under construction in Morgantown,
West Virginia.
Mylan Inc. owns a production and office facility in Caguas, Puerto Rico
containing 115,000 square feet and a production facility in Cidra, Puerto Rico
containing 32,000 square feet.
Bertek Pharmaceuticals, Inc. owns production, warehouse and office
facilities in two buildings in Sugar Land, Texas containing 70,000 square feet.
Mylan Technologies Inc. owns production, warehouse, laboratory, and office
facilities in three buildings in Swanton and St. Albans, Vermont containing
118,000 square feet. Mylan Technologies Inc. also operates a coating and
extrusion facility in St. Albans containing 71,000 square feet under a lease
expiring in 2015.
UDL Laboratories Inc. owns production, laboratory, warehouse, and office
facilities in three buildings in Rockford, Illinois and Largo, Florida
containing 123,000 square feet. UDL also leases a warehouse facility in Rockford
containing 41,000 square feet under a lease expiring in 2005.
<PAGE> 6
Penederm Inc. maintains administrative and research and development
facilities in two buildings in Foster City, California containing 27,000 square
feet under leases expiring in 2003.
The Company's production equipment includes that equipment necessary to
produce and package tablet, capsule, aerosol, liquid, transdermal and powder
dosage forms. The Company maintains seven analytical testing laboratories for
quality control.
The Company's production facilities are operated primarily on a two-shift
basis. Properties and equipment are well maintained and adequate for present
operations.
The Company's corporate offices, approximately 7,000 square feet, are
located at 1030 Century Building, 130 Seventh Street, Pittsburgh, Pennsylvania,
and are occupied under a lease expiring in 2000.
Item 3. Legal Proceedings
In August 1997, Key Pharmaceuticals filed suit in the United States
District Court for the Western District of Pennsylvania against the Company and
certain subsidiaries alleging patent infringement relating to the marketing of
its nitroglycerin transdermal system. The relief sought included a preliminary
and permanent injunction, treble damages along with interest and attorney's fees
and expenses. All claims and counterclaims were dismissed during fiscal 1999
pursuant to a settlement between the companies. The Company continues to
manufacture and market its nitroglycerin transdermal system in accordance with
the settlement.
In March 1999, a subsidiary of the Company entered into binding
arbitration related to a dispute with KaiGai Pharmaceutical, Co., Ltd.
("KaiGai"). The dispute arose out of a license and supply agreement for
nitroglycerin transdermal patches that both companies have asserted has been
breached by the other party. KaiGai seeks damages in excess of $20,000,000. The
Company believes the action against it is without merit and intends to
vigorously defend its position.
In June 1998, the Company filed suit in the Los Angeles Superior Court
against VivoRx Inc. ("VI"), VivoRx Diabetes, Inc. ("VDI") and certain directors.
The Company's suit alleges the defendants have been guilty of fraud,
mismanagement, abuse of authority, unfairness to the Company and other
shareholders and have wasted and misapplied the property of VI and VDI. In March
1999, VI, VDI and certain directors filed an answer to and cross-complaint in
Los Angeles Superior Court against the Company. The cross-complaint alleges
negligence, misrepresentation, fraud, breach of contract, and tortuous
inducement of breach of fiduciary duty. The suit seeks unspecified compensatory
and punitive damages. With respect to the cross-complaint the Company believes
the suit is without merit and intends to vigorously defend its position.
Upon motions made by the Company, certain disputes relating to the
exclusive licensing agreement between VI, VDI and the Company were referred to a
separate arbitration proceeding to be conducted under the auspices of the
American Arbitration Association. Such proceeding concluded in April 1999 and on
May 18, 1999, the Company received notice of the arbitrator's decision.
Under the terms of the arbitration award, the Company is required to fund
approximately $10 million for research and development performed by VI
subsequent to March 31, 1998. In turn, the Company was permitted, at its
election, either to (1) continue in effect and continue funding the exclusive
licensing agreement between the parties, or (2)terminate its rights under the
agreement and receive payment from VI of approximately $18 million, representing
50% of the amounts it has funded for research and development to date (including
the $10 million discussed above). The Company elected to terminate the agreement
and, therefore, VI must pay to it the amounts due, plus interest, in five annual
installments commencing October 1, 2000. This obligation is to be secured by a
security interest in VI's diabetes-related U.S. patents.
As a result of this award, the Company recorded the effects of the $10
million funding obligation discussed above in its fiscal 1999 financial
statements as research and development expense. The $18 million required to be
paid by VivoRx will be recognized as income when realized.
Various other disputes between the Company and VI, VDI and other parties
remain the subject of on-going litigation. While it is not feasible to
<PAGE> 7
predict the ultimate outcome of this litigation, it is the opinion of management
that the ultimate outcome will not have a material adverse effect on the
Company's operations or its financial position.
In May 1998, Genpharm Inc. filed in the general division of Ontario
Court, Canada, a statement of claim against Novopharm Limited and Granutec, Inc.
("Novopharm"). The claim was filed to resolve contract interpretation issues and
collect additional funds due relating to an agreement between the parties for
the sale of ranitidine. In July 1998, Novopharm filed a counterclaim against
Genpharm and the Company seeking damages of up to $60,000,000. The Company was
named in the counterclaim due to its agreement with Genpharm in which it shared
in profits derived from the product ranitidine. The Company believes the
counterclaim is without merit and intends to vigorously to defend its position.
On December 22, 1998, the Federal Trade Commission ("FTC") filed suit in
federal district court for the District of Columbia against the Company. The
FTC's complaint alleges the Company engaged in restraint of trade,
monopolization, attempted monopolization and conspiracy to monopolize, arising
out of certain agreements involving the supply of raw materials used to
manufacture two drugs. The FTC also sued in the same case the foreign suppliers
of the raw materials, the supplier's parent company and its United States
distributor. Under the terms of the agreements related to these raw materials,
the Company has agreed to indemnify these parties.
The Company is a party to other suits involving the Attorneys General from
33 states and more than 20 putative class actions that allege the same conduct
alleged in the FTC suit as well as alleged violations of state consumer
protection laws. A qui tam action was commenced by a private party in the U.S.
District Court for the District of South Carolina proportedly on behalf of the
United States alleging violations of the False Claims Act and other statues. The
relief sought by the FTC includes an injunction barring the Company from
engaging in the challenged conduct, recision of certain agreements and
disgorgement in excess of $120,000,000. The states and private parties seek
similar relief, treble damages and attorneys' fees. In addition, a class action
suit was filed alleging violations of federal securities laws by the Company and
certain directors and officers of the Company.
Without specifying a dollar amount, the suit seeks compensatory damages.
Since the date of the filing of the Company's quarterly report of Form 10-Q
for the quarter ended December 31, 1998, there have been no material
developments in these proceedings except as described below. The Company has
filed motions to dismiss the FTC and State Attorneys' General cases as well as
the federal securities case filed in U.S. Federal District Court for the Western
District of Pennsylvania. The Company has also filed motions to dismiss five of
the suits commenced by private parties. In addition, two other private actions
have been dismissed.
The Company believes that it has meritorious defenses to the claims in all
FTC and related suits and intends to vigorously defend them. Although the
Company believes it has meritorious defenses to the claims, an adverse result in
these suits could have a material adverse effect on the Company's financial
position and results of its operations.
The Company is involved in various other legal proceedings that are
considered normal to its business. While it is not feasible to predict the
ultimate outcome of such proceedings, it is the opinion of management that the
outcome of these suits will not have a material adverse effect on the Company's
operations, financial position, or liquidity.
Item 4. Submission of Matters to a Vote of Security Holders
Not applicable.
EXECUTIVE OFFICERS OF THE REGISTRANT
The names, ages and positions of the Company's executive officers are as
follows:
Milan Puskar 64 Chairman, Chief Executive Officer and
President
Dana G. Barnett 58 Executive Vice President
Louis J. DeBone 53 Senior Vice President
Roger L. Foster 52 Vice President and General Counsel
Roderick P. Jackson 59 Senior Vice President
Donald C. Schilling 49 Vice President-Finance
Patricia A. Sunseri 59 Vice President-Investor and
Public Relations
Robert W. Smiley 77 Secretary
<PAGE> 8
Mr. Puskar was employed by the Company from 1961 to 1972 and served in
various positions, including Secretary-Treasurer, Executive Vice President and a
member of the Board of Directors. From 1972 to 1975, Mr. Puskar served as Vice
President and General Manager of the Cincinnati division of ICN Pharmaceuticals
Inc. In addition, he has served as a partner in several pharmaceutical firms in
foreign countries and is currently a director of VivoRx, Inc., Santa Monica,
California; West Virginia University Foundation, Morgantown, West Virginia; and
Duquesne University, Pittsburgh, Pennsylvania. Mr. Puskar has served as
President of the Company since 1976 and as Vice Chairman of the Board since
1980. He was elected Chairman of the Board and Chief Executive Officer in
November 1993.
Mr. Barnett was employed by the Company in 1966. His responsibilities have
covered production, quality control and product development. Mr. Barnett became
Vice President in 1974, Senior Vice President in 1978 and Executive Vice
President in 1987. He was elected President and Chief Executive Officer of
Somerset in June 1991, and in August 1995, he was elevated to Chairman and Chief
Executive Officer.
Mr. DeBone has been employed by the Company since September 1987. Prior to
assuming his present position in May 1999, he served as Vice
President-Operations and Vice President-Quality Control. Since February 1997, he
has also served as President of Mylan Technologies Inc. He was previously
employed with the Company from March 1976 until June 1986 as Director of
Manufacturing.
Mr. Foster has been employed by the Company since May 1984. Prior to
assuming his present position in June 1995 as Vice President and General Counsel
he served as Director of Legal Services and as Director of Governmental Affairs.
Mr. Jackson has been employed by the Company since March 1986. Prior to
assuming his present position in October 1992 as Senior Vice President, he
served as Vice President-Marketing and Sales.
Mr. Donald C. Schilling has been employed by the Company since October
1997. Prior to assuming his present position as Vice President-Finance, he was
Vice President of Finance & Administration for Plastics Manufacturing Inc. in
Harrisburg, NC from 1991 to 1997.
Mrs. Sunseri has served as a Director of the Company since April 1997, as
Vice President-Investor and Public Relations of the Company since 1989 and as
Director of Investor Relations of the Company from 1984 to 1989.
Mr. Smiley has been the Secretary and a member of the Board of
Directors of the Company for over 23 years. He joined the law firm of Doepken
Keevican & Weiss Professional Corporation in October, 1992, which law firm
provided legal services to the Company in fiscal 1999. Previously, he was a
partner of Smiley, McGinty & Steger for more than five years.
No family relationships exist between any of the above executive
officers. Officers of the Company serve at the pleasure of the Board of
Directors.
PART II
Item 5. Market for Registrant's Common Equity and
Related Stockholder Matters
The information required by Item 5 is hereby incorporated by reference to
pp. 21 and 49 of the accompanying Annual Report to Shareholders for the year
ended March 31, 1999.
Item 6. Selected Financial Data
The information required by Item 6 is hereby incorporated by reference to
p. 21 of the accompanying Annual Report to Shareholders for the year ended March
31, 1999.
Item 7. Management's Discussion and Analysis of Financial Condition and
Results of Operations
<PAGE> 9
The information required by Item 7 is hereby incorporated by reference to
pp. 22-29 of the accompanying Annual Report to Shareholders for the year ended
March 31, 1999.
Item 7A. Quantitative and Qualitative Disclosures About Market Risk The
information required by Item 7A is hereby incorporated by reference to p. 28 of
the accompanying Annual Report to Shareholders for the year ended March 31,
1999. Item 8. Financial Statements and Supplementary Data The information
required by Item 8 is hereby incorporated by reference to pp.
30-49 of the accompanying Annual Report to Shareholders for the year ended March
31, 1999.
Item 9. Changes in and Disagreements with
Accountants on Accounting and Financial Disclosure
Not applicable.
PART III
Item 10. Directors and Executive Officers of the Registrant
The information as to directors required by Item 10 is hereby incorporated
by reference to pp. 2 and 3 of the Company's 1999 Proxy Statement. Information
concerning executive officers is provided in PART I of this report under the
caption "Executive Officers of the Registrant".
Item 11. Executive Compensation
The information required by Item 11 is hereby incorporated by reference to
pp. 8-10 of the Company's 1999 Proxy Statement.
Item 12. Security Ownership of Certain Beneficial Owners and Management The
information required by Item 12 is hereby incorporated by reference topp. 4 and
5 of the Company's 1999 Proxy Statement.
Item 13. Certain Relationships and Related Transactions
The information required by Item 13 is hereby incorporated by reference to
p. 2 of the Company's 1999 Proxy Statement.
PART IV
Item 14. Exhibits, Financial Statement Schedules, and Reports on Form 8-K
(a) 1. List of Financial Statements
Annual Report
Page
Number
INCLUDED IN ANNUAL REPORT TO SHAREHOLDERS:
Consolidated Balance Sheets.............................. 30-31
Consolidated Statements of Earnings...................... 32
Consolidated Statements of Shareholders' Equity and
Comprehensive Earnings................................. 33
Consolidated Statements of Cash Flows.................... 34-35
Notes to Consolidated Financial Statements............... 36-48
Independent Auditors' Report............................. 48
2. Financial Statement Schedules
The information required by this Item is incorporated herein
by reference to Exhibit 99. All other schedules have been
omitted because they are not required or the information can
be derived from the Consolidated Financial Statements
included in the accompanying Annual Report to Shareholders
for the year ended March 31, 1999.
3. Exhibits
(3)(a) Amended and Restated Articles of Incorporation of the
registrant, filed by the Company as Exhibit 4.2 to the
Form S-8 on December 23, 1997 (registration number
333-43081) and incorporated herein by reference.
<PAGE> 10
(b) By-laws of the registrant, as amended to date, filed by
the Company as Exhibit 4.3 to the Form S-8 on December
23, 1997 (registration number 333-43081) and
incorporated herein by reference.
(4)(a) Rights Agreement dated as of August 22, 1996, between
the Company and American Stock Transfer & Trust Co.,
filed as Exhibit 4.1 to Form 8-K dated August 30, 1996
and incorporated herein by reference.
(10)(a)Mylan Laboratories Inc. 1986 Incentive Stock Option Plan,
as amended to date, filed as Exhibit 10(b) to Form 10-K
for fiscal year ended March 31, 1993 and incorporated
herein by reference.
(b) "Salary Continuation Plan" with Milan Puskar, Dana G.
Barnett and C.B. Todd each dated January 27, 1995 and
filed as Exhibit 10(b) to Form 10-K for fiscal year
ended March 31, 1995 and incorporated herein by
reference.
(c) "Salary Continuation Plan" with Louis J. DeBone dated
March 14, 1995 filed as Exhibit 10(c) to Form 10-K for
fiscal year ended March 31, 1995 and incorporated herein
by reference.
(d) Employment contract with Milan Puskar dated April 28,
1983, as amended to date, filed as Exhibit 10(e) to Form
10-K for fiscal year ended March 31, 1993 and
incorporated herein by reference.
(e) Split Dollar Life Insurance Arrangement with McKnight
Irrevocable Trust filed as Exhibit 10(g) to Form 10-K
for fiscal year ended March 31, 1994 and incorporated
herein by reference.
(f) "Service Benefit Agreement" with Laurence S. DeLynn,
John C. Gaisford, M.D., and Robert W. Smiley, Esq. each
dated January 27, 1995 and filed as Exhibit 10(g) to
Form 10-K for fiscal year ended March 31, 1995 and
incorporated herein by reference.
(g) Split Dollar Life Insurance Arrangement with Milan
Puskar
Irrevocable Trust filed as Exhibit 10(h) to Form 10-K
for the fiscal year ended March 31, 1996 and
incorporated herein by reference.
(h) Split Dollar Life Insurance Arrangement with the Todd
Family Irrevocable Trust filed as Exhibit 10(i) to Form
10-K for the fiscal year ended March 31, 1997 and
incorporated herein by reference.
(i) Split Dollar Life Insurance Arrangement with the Dana G.
Barnett Irrevocable Family Trust filed as Exhibit 10(j)
to Form 10-K for the fiscal year ended March 31, 1997
and incorporated herein by reference.
(j) "Salary Continuation Plan" with Patricia Sunseri dated
March 14, 1995 filed as Exhibit 10(k) to Form 10-K for
the fiscal year ended March 31, 1997 and incorporated
herein by reference.
(k) Mylan Laboratories Inc. 1997 Incentive Stock
Option Plan filed as Annex A to the 1998 Proxy
Statement and incorporated herein by reference.
(l) Mylan Laboratories Inc. 1992 Nonemployee Director
Stock Option Plan, as amended to date, filed as
Exhibit 10(l) to Form 10-K for the fiscal year
ended March 31, 1998 and incorporated herein by
reference.
(m) "Salary Continuation Plan" with Roderick P. Jackson
dated March 14, 1995 and Amendment No. 1 dated April 1,
1999, filed herewith.
(13) Fiscal 1999 Annual Report to Shareholders which, except
for those portions incorporated by reference, is
furnished solely for the information of the Securities
and Exchange Commission and is not deemed to be
"filed".
(21) Subsidiaries of the registrant, filed herewith.
(23) Consents of Independent Auditors, filed herewith.
(27) Financial Data Schedule, filed herewith.
(99) Consolidated financial statements of Somerset
Pharmaceuticals, Inc. for years ended December 31, 1998,
1997, and 1996, filed herewith.
(b) Reports on Form 8-K
The Company was not required to file a report on Form
8-K during the quarter ended March 31, 1999.
<PAGE> 11
SIGNATURES
Pursuant to the requirements of section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this Report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Date: June 23, 1999
by /S/ MILAN PUSKAR
Milan Puskar
Chairman, Chief Executive Officer and President
Pursuant to the requirements of the Securities Exchange Act of 1934,
this Report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.
/S/ MILAN PUSKAR June 23, 1999 /S/ DANA G. BARNETT June 23, 1999
- - ------------------------ ---------------------------
Milan Puskar Dana G. Barnett
Chairman, Chief Executive Officer and President Executive Vice President
(Principal executive officer) and Director
/S/ LAURENCE S. DELYNN June 23, 1999 /S/ ROBERT W. SMILEY June 23, 1999
- - ------------------------ ---------------------------
Laurence S. DeLynn Robert W. Smiley
Director Secretary and Director
/S/PATRICIA A. SUNSERI June 23, 1999 /S/JOHN C. GAISFORD,M.D. June 23, 1999
- - ------------------------ ---------------------------
Patricia A. Sunseri John C. Gaisford,M.D.
Vice President and Director Director
/S/ C.B. TODD June 23, 1999 /S/ DONALD C. SCHILLING June 23, 1999
- - ------------------------ ---------------------------
C.B. Todd Donald C. Schilling
Director Vice President-Finance
(Principal financial officer)
/S/ Frank A. DeGeorge June 23, 1999
---------------------------
Frank A. DeGeorge
Director of Corporate Finance
(Principal accounting officer)
Amendment No. 1 to the
Retirement Benefit Agreement
This Amendment No. 1 is made and effective this 1st day of April, 1999.
WHEREAS, Mylan Laboratories Inc. ("Mylan") and Roderick P. Jackson
("Employee") entered into that certain Retirement Benefit Agreement as of March
14, 1995 (the "Agreement") and now wish to amend the Agreement as provided
herein to induce Employee to continue his employment with Mylan.
NOW, THEREFORE, the Agreement is hereby amended as follows:
1. A new Section 3.7 is added to the Agreement, and old Sections 3.7
through 3.9 are renumbered accordingly:
"3.7 Should Employee Retire after March 31, 2002 he shall receive
two hundred fifty thousand dollars ($250,000) each year for fifteen
(15) years."
2. A new sentence is added at the end of Section 3.8 (formerly Section
3.7):
"Should Employee become unable to perform the material and
substantial duties of his position on or after March 31, 1999, he
shall receive, pursuant to ss. 4.1, two hundred fifty thousand dollars
($250,000) per year for fifteen (15) years in lieu of any benefit
specified in Sections 3.2 through 3.7"
3. Section 6.1 is restated as follows:
"6.1 Upon a Change of Control prior to March 31, 1999, Jackson
shall receive, in lieu of the annual payments provided for under
Article III, the NPV of One Hundred Thousand Dollars ($100,000.00) per
year for ten (10) years; provided Jackson is employed by the Company
at or immediately prior to the Change of Control.
Upon a Change of Control on or after March 31, 1999, Jackson
shall receive, in lieu of the annual payments provided for under
Article III, the NPV of Two Hundred Fifty Thousand Dollars
($250,000.00) per year for fifteen (15) years; provided Jackson is
employed by the Company at or immediately prior to the Change of
Control."
4. A new Section 10.4 is added as follows:
"10.4 Notwithstanding any provision of this Agreement to the
contrary, if a Change in Control occurs at any time (before or after
Retirement), then this Article X will become inoperative.
<PAGE>
5. Section 25.1(a) is amended as follows:
"(a) The maximum benefit to which Employee is entitled under
Article III shall not exceed two hundred fifty thousand dollars
($250,000) per year for fifteen (15) years.
IN WITNESS WHEREOF, in accordance with Article XVI of the Agreement,
and intending to be legally bound, the parties hereto have signed (or
caused their authorized agents to sign) this Amendment effective as of the
date first above noted.
MYLAN LABORATORIES INC. RODERICK P. JACKSON
By: /s/ Milan Puskar CEO /s/ Roderick P. Jackson
___________________________ _____________________________
Title
Mylan.
A company diversified.
Mylan is a company on the move. Through acquisitions and alliances, we have
expanded our product mix and moved beyond the solid dosage form of tablets and
capsules.
About Mylan Laboratories Inc.
Mylan Laboratories Inc. and its subsidiaries are engaged in the
development, licensing, manufacturing, marketing and distributing of generic and
proprietary pharmaceutical, wound care and dermatological products. We are a
diversified pharmaceutical company with a core generic business, a growing
branded presence and varied drug delivery capabilities. Mylan Pharmaceutical
Inc., the generic division of the company, has a growing product portfolio
consisting of more than 105 prescription products covering 33 therapeutic
categories. The Company sells these products to proprietary and ethical
pharmaceutical wholesalers and distributors, drug store chains, drug
manufacturers and public and governmental agencies. The branded division of the
Company, Bertek Pharmaceuticals Inc., markets eight proprietary products through
its detail sales force. Bertek is responsible for the development and promotion
of all branded products including wound care, dermatology, branded transdermal
patches and solid oral medications. Mylan is a pharmaceutical company with
expanding capabilities in research and development, marketing and distribution.
We are exploring a full range of delivery channels for a widening range of
products. We are building the company through strategic alliances, acquisitions
and agreements, and we are aggressively focused on new product development. For
the past 38 years our reputation has been built on integrity and on the ability
to provide quality, service and prompt delivery to our customers. Mylan has
become a leading player in the marketplace and it is our intention to be an even
stronger presence in the future.
Bertek Branded Products
Bertek Pharmaceuticals Inc., the branded drug division of Mylan, was formed
in late 1996, to market acquired and internally developed branded
pharmaceuticals. The three therapeutic areas of concentration include
cardiology, neurology and dermatology. The cardiology focus is built upon the
Maxzide(R) franchise, and has expanded to now include Clorpres(TM)
(anti-hypertensive), and Nitrek(R) (Nitroglycerin Transdermal), which are sold
by Bertek's sales force to general practitioners, internists and cardiologists.
Mylan has several compounds in development such as Dotarizine for migraine
headaches, and Apomorphine for the on/off fluctuations associated with
Parkinson's disease, that upon approval, will be key components in the area of
neurology. The key driver to Mylan's presence in dermatol-ogy is Penederm, which
adds three marketed dermatology products, near-term and long-term R&D
opportunities and topical drug delivery technologies. Penederm is a great
strategic fit for Bertek. In addition to selling the three Penederm products to
dermatologists, these products are also detailed by the primary care sales
force. Bertek also markets burn and wound care products via their institutional
sales force and has a dedicated managed care group to service that arena. As
products are added to Bertek's branded portfolio, the primary care sales force
must expand. Therefore, Bertek has implemented the hiring of 25 sales reps per
quarter for the primary care group until the sales force grows to approximately
250-300 reps. The Company believes a force of that size should provide the
critical mass for the products currently marketed and in development.
Mylan Acquires Exclusive Rights to Zagam(R)
Mylan acquired the exclusive U.S. rights to manufacture and market Zagam(R)
(Sparfloxicin) from Rhone-Poulenc Rorer in August 1998. Zagam(R) is a patent
protected oral antibiotic indicated for the treatment of community-acquired
pneumonia and chronic bronchitis. Bertek Pharmaceuticals Inc. launched Zagam(R)
into theprimary care, institutional and managed care markets, October 23, 1998.
-5-
<PAGE>
Penederm
Penederm Inc. specializes in the development and marketing of unique
dermatology products. The current product portfolio consists of three topical
prescription products Avita(R), Mentax(R) and Acticin(R). Avita(R) offers
dermatologists and patients a milder formulation of retinoic acid for the
treatment of acne with excellent efficacy utilizing their TopiCare Delivery
Compounds(R). Avita(R) cream was launched in 1997, followed by the Avita(R) gel
formulation in early 1998. Mentax(R), is a prescription topical antifungal cream
for the treatment of athlete's foot (tinea pedis), groin fungus (tinea cruris)
and ringworm (tinea corporis). Mentax(R) has been approved by the FDA for
athlete's foot by treating twice a day for only one-we ek. This definitive
one-week treatment strengthens the positioning of Mentax(R) in the antifungal
market, providing a good point of differentiation from those antifungal
products, which require treatment for up to four weeks. In 1998, Penederm
launched Permethrin 5% cream under the Penederm brand-name Acticin(R).
Acticin(R) is a topical prescription product for the treatment of scabies.
In October 1998, Mylan acquired Penederm Inc., an emerging specialty
pharmaceutical company with emphasis in the field of dermatology. Penederm
currently has three approved prescription products and a rich pipeline of
promising products under active development utilizing their proprietary TopiCare
Delivery Compounds(R).
Avita(R) is one of a new generation of topical retinoic acid treatments for
acne. Avita(R) offers dermatologists and patients a mild formulation of retinoic
acid with excellent efficacy. Acticin(R) is a topical application for the
treatment of scabies infection. A single application of Acticin(R) applied to
the entire body generally cures the scabies infection.
-6-
<PAGE>
Penederm Technology
Penederm's pipeline represents promising near-term and long-term growth
opportunities. Penederm's technology foundation offers many opportunities for
new drug introduction in the future. These opportunities may include second
generation Mentax(R) products in different formulations or for new indications.
The Company is also making progress on two new therapies, a form of Mentax(R)
for nail fungus and a vitamin D analog for psoriasis. Penederm also has active
Phase II programs evaluating a Vitamin D derivative for the treatment of
psoriasis and advanced retinoic acid formulations for the treatment of actinic
keratosis and related indications. Mentax(R) is currently approved for three
types of skin fungal infections. The fourth indication, tinea versicolor (a
fungal infection characterized by irregular patches of lighter or darker
pigmentation surrounding the skin), entered Phase III study in April. The
protocol calls for two, 130 patient studies at ten trial sites for a 12-month
duration. In addition to its approved use against skin fungal infections,
Mentax(R) also has potential as a treatment for onychomycosis (nail fungus). It
is estimated that 12 million people now suffer from this condition and side
effects and difficulty of administration limit the only treatments currently
available. It is anticipated that Penederm's current R&D efforts will not only
continue, but will be expanded to include some of Mylan's research projects that
have the potential to be improved by Penederm's drug delivery technology.
Mylan continues to increase its emphasis and make significant investments
in research and development New product development is essential as the Company
expands into the branded arena. Currently, there are four proprietary products
in advanced clinical testing. Dotarizine is a novel product indicated for the
prophylaxis of migraine head-aches. We have successfully completed a 429
patient, Phase II study and are presently preparing for two double blind, 800
patient Phase III efficacy trials. Phase III clinicals should begin in mid 1999,
and take approximately 12 to 18 months for completion. The second compound,
Sertaconazole, is a topical antifungal that was licensed from Ferrer in
Barcelona, Spain. Sertaconazole is currently in advanced Phase III study with an
anticipated NDA filing in calendar 1999. Apomorphine is indicated for the on/off
fluctuations in late stage Parkinson's disease. The Phase II study has been
completed and meetings have been held with the FDA to discuss the protocol for
Phase III clinicals. The final compound in development is a wound care product
for diabetic foot ulcers. This unnamed compound is a second-generation product
with orphan drug status and novel delivery. The Phase II study has been
completed and Phase III will consist of two parallel studies involving 400
patients each, with a projected completion of 12 to 18 months.
-7-
<PAGE>
Cystagon(R)
Five years ago, in August of 1994, the FDA awarded Mylan Orphan Drug
Approval for Cystagon(R). This novel compound is indicated for the treatment of
Nephropathic Cystinosis, a very rare genetic disorder that afflicts children and
adults. Prior to the advent of Cystagon(R), Cystinosis led to a progressive
decline in renal function and often to end- stage renal failure. Therefore,
Cystagon(R) is an important medical advance in the management of this condition.
Approximately 250 patients in the United States are being treated for this
disease. Due to the small patient population, Mylan utilizes Chronimed as the
specialized U.S. distributor for this product.
Receiving FDA approval for Cystagon(R) was a particularly proud moment for
everyone at Mylan. However, our commitment to the patients diagnosed with this
devastating disease reached far beyond the U.S. to the hundreds of patients
throughout the world who were in desperate need for a treatment. Through the
efforts of Mylan and Orphan Europe, Cystagon(R) was the first orphan drug to be
approved under the European Union Centralized System in June of 1997. Today 312
patients within the EU countries are being treated. Product is also available to
patients in other European countries and the Middle East on a named patient
basis.
It is estimated that approximately 355 patients are being treated with
Cystagon(R) in Europe and the Middle East with the total patient population in
those regions estimated to be 500-600 patients.
Mylan received FDA approval for Sulfamylon(R) Powder for 5% Topical
Solution (Mafenide Acetate) June 15, 1998. Sulfamylon(R) is indicated for use as
an adjunctive topical anti-microbial agent to control bacterial infection when
used under moist dressing over meshed autografts on excised burn wounds.
Sulfamylon(R) is the first drug approved for this indication and it has
orphan drug status. The Bertek Institutional sales force launched Sulfamylon(R)
July 15, 1998, targeting 144 burn centers throughout the U.S.
Mylan, your partner in quality, the name you can trust. With American's
health and well being at stake, quality must always be the primary consideration
in dispensing the pharmaceutical products that bear our label. For more than 38
years, Mylan has considered quality before all else in everything we do from
research and development to manufacturing and distribution. That is why our name
is synonymous with quality throughout the pharmaceutical industry.
Sulfamylon
-8-
<PAGE>
Product opportunities often require certain drug delivery or manufacturing
technologies. Mylan has a network of strategic alliances that provide access to
these unique technologies.
Mylan has had an ongoing product development collaboration with Penwest
Ltd.; whereby the companies develop oral controlled release formulations
utilizing Penwest's patented TIMERx(R) delivery technology. This collaboration
covers three products: Procardia XL(R), Glucotrol XL(R) and Adalat CC(R). Mylan
filed the first ANDA for 30mg. Nifedipine ER (Procardia XL(R)) utilizing
TIMERx(R) in June of 1997 and received tentative approval for the product March
15, 1999. As the first company to file its application with the FDA for this
product, Mylan will be entitled to 180 days of exclusivity upon product launch.
Mylan has also signed an exclusive licensing agreement with Meridian
Medical Technologies, a worldwide leader in the development of auto-injector
drug delivery systems. Under the agreement, Meridian will license, manufacture
and supply a line of generic injectable drugs to Mylan for marketing and
distribution. Meridian had submitted three product applications to the FDA for
hospital use, and on March 9, 1999, the FDA approved Meridian's application for
Acyclovir injection, a generic drug for the treatment of herpes and shingles.
Bertek Pharmaceuticals Inc. will be responsible for the marketing of this
product upon its launch.
TopiCare delivery technology delivers larger polymer molecules in the upper
layers of the skin (A), while smaller molecules are deposited in the deeper
layers (B). This unique system can reduce skin irritation and can enhance the
duration of the medication.
Penederm, based in Foster City, California, is a drug delivery company with
a market focus in dermatology. Through its proprietary TopiCare Delivery
Compounds(R), Penederm develops and markets topically administered prescription
dermatological products. The patented TopiCare delivery technology consists of a
group of liquid polymers designed to hold skin care agents at targeted levels on
and in the upper layers of the skin. These compounds have been shown to have the
potential to prevent wash off by repeated contact with water, enhance the
duration of action of active ingredients, reduce dosage requirements, and reduce
irritation common to many dermatological medications.
Because of their efficacy, safety, flexibility and ease of development,
TopiCare delivery technology can be applied to a number of compounds Mylan
currently has in development, as well as Penederm's own pipeline of prescription
dermatological products. This provides Mylan with proven effective technology
for topical pharmaceutical delivery.
strategic alliances
-9-
<PAGE>
Mylan Technologies Inc. is a leading manufacturer of transdermal drug
delivery systems with unique state-of-the-art technologies for producing
finished pharmaceutical products. Transdermal drug delivery has proven to be
more effective than traditional oral delivery in certain pharmaceutical
applications. It offers many advantages over existing delivery such as ease of
use, improved compliance and market expansion for existing drugs. The patches
developed by Mylan are smaller and more cosmetically elegant than traditional
patches and since they cover less area, they can reduce common side effects such
as skin irritation.
Mylan Technologies is actively involved in a variety of R&D projects
utilizing transdermal drug delivery technology to provide new products for
marketing by Mylan subsidiaries. The first product to be approved and marketed
utilizing this unique delivery system was the Nitroglycerin Transdermal System,
marketed by Mylan Pharmaceuticals, which is bioequivalent and therapeutically
equivalent to Transderm Nitro(R), and also marketed by Bertek Pharmaceuticals
Inc. as Nitrek(R). Mylan has applied this advanced delivery technology to other
products that are currently filed with the FDA and in development.
Transdermal drug delivery, the delivery of medication into the skin or
through the skin into the bloodstream has proven to be more efficacious for
certain applications than traditional oral drug delivery. Transdermal Drug
Delivery Systems by Mylan Technologies offers a completely integrated source
from the initial concept through final manufacturing.
-10-
<PAGE>
Prescription products dispensed in unit-dose packaging provide a distinct
marketing advantage in the institutional marketplace. The UDL Laboratories
division of Mylan manufactures, repackages and markets multi-source and
single-source pharmaceutical products in unit-dose packaging to the
institutional marketplace. UDL offers a broad range of multi-source products,
more than 450 line items, including oral solid, oral liquid and injectable
dosage forms, and special use packaging such as Emergi-script, Bingo,
Control-A-Dose, and Robot Ready. A nine-person detail sales force, targeting
more than 6000 hospitals throughout the U.S., markets the full product line.
UDL augments Mylan's generic business by not only repackaging Mylan generic
products but also contracting products from other manufactures for packaging.
UDL is dedicated to the development of generic liquid products. Via their
specialized liquid manufacturing facility in Largo, Florida, UDL produces more
than 80 liquid products for the institutional market. In June of 1998, the
Company received FDA approval for Nystatin Oral Suspension which compares to
Mycostatin(R) Mark Oral Suspension, and in March of 1999, the Company received
approval for Albuteral Sulfate Oral Solution, which compares to Proventil(R).
Presently, there are three applications filed with the FDA and an additional
seven products are in various stages of development.
Extended Release
Drug delivery has become one of the fastest growing areas of the
pharmaceutical industry. Branded pharmaceutical companies are using drug
delivery as a means of extending patent life, differen-tiating their products
and increasing market share. In today's pharmaceutical marketplace many products
whose patents have expired or will expire have complicated drug delivery
systems.
Mylan's growth strategy has been to target these complex "niche"
opportunities. Mylan has made a commitment to complex drug formulation and
manufacturing by internally developing specialized bead technologies. Mylan has
the ability to formulate products with complex extended release drug delivery
such as Verapamil HCl ER Capsules, which compares to Verelan(R).
Complex extended release formulations often require specialized equipment
for manufacturing. Therefore, the Company has dedicated a 27,000 square foot
manufacturing facility in which it houses state-of-the-art equipment such as the
technical machinery that is essential to manufacture Diltiazem HCl ER Capsules,
which compares to Dilacor XR(R) and Diltiazem HCl ER Capsules which compares to
Cardizem SR(R).
Mylan's leadership position in the generic drug industry is strengthened by
the Company's expertise in developing and commercially manufacturing extended
release and delayed release generic pharmaceuticals.
To date, Mylan has introduced four compounds utilizing its extended release
bead and matrix technology. Additionally, there are 12-14 compounds in various
stages of development that target branded sales of approximately $7 billion.
-11-
<PAGE>
The environment for Mylan's core generic business has never been better.
Patent expirations are the catalyst driving the generic industry as a source of
new product opportunities. According to industry analysts, approximately $41
billion in branded drug sales will be coming off patent throughout the next
decade. Additionally, there are products valued at $7 billion that are off
patent with no generic competition.
MylanPharmaceuticals consistently ranked #1 in the number of new and refilled
prescriptions dispensed among all pharmaceutical companies, brand or generic as
tracked by the 1998 IMS National Prescription Audit.
-12-
<PAGE>
2000
Strategic Alliances
Mylan has been actively seeking strategic alliances to expand its product
line and geographic reach in the market place. In January the company reached an
agreement with Genpharm Inc. of Canada, whereby the companies will co-develop
and Mylan will exclusively market and distribute in the U.S. certain products
Genpharm has in research. The agreement includes 15 branded and generic products
in a variety of dosage forms, including immediate release tablets and capsules,
injectables, controlled and sustained release tablets, nasal sprays and
sublingual sprays. The first product submission has been filed and additional
filings are anticipated to occur in the near future. This agreement furthers a
strategy of Mylan's which is to have products that cover niche areas in the
marketplace.
Mylan's agreement with Draxis Pharmaceutial of Canada provides the
framework for an ongoing collaboration under which Draxis will introduce certain
Mylan products in Canada. Draxis has two appli-cations filed in Canada based on
this alliance. Mylan's alliance with Draxis will enable the Company to expand
the geographic reach of its products into Canada and share the profits from
these Canadian sales without the investments that would otherwise be required to
enter the Canadian market.
Two new generic products now carry the Mylan label via an exclusive
licensing agreement with 3M Pharmaceuticals, Orphenadrine Citrate ER Tablets and
Orphenadrine Citrate, Aspirin and Caffeine Tablets. Orphenadrine Citrate ER is
therapeutically equivalent to Norflex(TM), and is used as a skeletal muscle
relaxant, as is Orphenadrine Citrate, Aspirin and Caffeine Tablets, which is
therapeutically equivalent to Norgesic(TM) and Norgesic(TM) Forte.
Looking to the future As we approach the 21st century, greater emphasis is
placed on our innovator products and drug delivery capabilities as a source of
growth. However, it has been our commitment to quality, reliability and
innovation that has made us a market leader in generic pharmaceuticals in the
20th century. Therefore, we are not looking to the future without regard to our
past. Mylan is a market leader and remains dedicated to being a market leader in
the generic drug industry.
The Business of Approvals
New product introductions are a key ingredient to sustain above average
sales and earnings growth in the generic pharmaceutical industry. Therefore,
Mylan has been aggressively researching and developing compounds to ensure a
steady stream of approvals. Over the past three years Mylan has received
approval for 26 generic products. In fiscal 1999, Mylan submitted 18 ANDAs to
the FDA and received final approval for eleven products, Clomipramine HCl,
Hydroxychloroquine Sulfate, Sulfamylon(R) for 5% Topical Solution, Nystatin Oral
Suspension, Glyburide, Ranitidine, Acyclovir, Clonazepam, Etodolac 500 mg.,
Albuteral Sulfate Syrup and Extended Phenytoin Sodium. Additionally, Mylan
received tentative approval for Terazosin HCl, Buspirone, Astemizole,
Fluoxetine, Verapamil HCl ER, Carbidopa & Levodopa ER and Nifedipine ER 30 mg.
Presently the Company has 35 ANDAs filed with the FDA targeting combined
branded sales of $9-$10 billion. Eight of these are tentatively approved and
will be launched upon the settlement of legal issues with the original NDA
holders or upon their patent expirations. Twenty additional applications have
been targeted for FDA filing in calendar 1999, with combined branded sales of
approximately $6 billion.
-13-
<PAGE>
Mylan Pharmaceuticals Inc. Generic Product Line
Generic Name Trade Name
- - ------------ ----------
Analgesic
- - ---------
Indomethacin Indocin (R)
Propoxyphene Compound Darvon (R)
Compound-65
Propoxyphene HCl Darvon (R)
Propoxyphene HCl & Acetaminophen Wygesic (R)
Propoxyphene Napsylate & Acetaminophen Darvocet-N (R) 100
Anti-Inflammatory
- - -----------------
Etodolac (Capsules) Lodine (R)
Etodolac Lodine (R)
Fenoprofen Calcium Nalfon (R)
Flurbiprofen Ansaid (R)
Ibuprofen Motrin (R)
Rufen (R)
Ketoprofen Orudis (R)
Ketorolac Tromethamine Toradol (R)
Meclofenamate Sodium Meclomen (R)
Naproxen Naprosyn (R)
Naproxen Sodium Anaprox (R)
Piroxicam Feldene (R)
Sulindac Clinoril (R)
Tolmetin Sodium Tolectin (R) DS
Tolmetin Sodium Tolectin (R) 600
Anti-malarial
- - -------------
*Hydroxychloroquine Sulfate Plaquenil (R)
Anti-obsessional
- - ----------------
*Clomipramine HCI Anafranil(R)
Antiangina
- - ----------
Atenolol Tenormin (R)
Nadolol Corgard (R)
Nitroglycerin Transdermal System(Patches)Transderm Nitro (R)
Verapamil HCl Isoptin (R)
Antianxiety
- - -----------
Alprazolam Xanax (R)
Diazepam Valium (R)
Lorazepam Ativan (R)
Perphenazine & Amitriptyline HCl Triavil (R)
Antianxiety/antipsychotic
- - -------------------------
Trifluoperazine HCl Stelazine (R)
Antibacterial Agent
- - -------------------
Nitrofurantoin Macrodanti (R)
Antibiotic
- - ----------
Cefaclor Ceclor (R)
Cefaclor (Oral Suspension) Ceclor (R)
Cephalexin Keflex (R)
Doxycycline Hyclate Vibramycin (R)
Doxycycline Hyclate Vibra-tabs (R)
Erythromycin Ethylsuccinate E.E.S. 400 (R)
Erythromycin Stearate Erythrocin (R) Stearate
Tetracycline HCl Achromycin V (R)
Sumycin (R)
Generic Name Trade Name
- - ------------ ----------
Anticonvulsant
*Clonazepam Klonopin (R)
* Extended Phenytoin Sodium Dilantin (R)
Kapseals (R)
Antidepressant
Amitriptyline HCl Elavil (R)
Chlordiazepoxide & Amitriptyline HCl Limbitrol (R)
Doxepin HCl Sinequan (R)
Maprotiline HCl Ludiomil (R)
Nortriptyline HCl Pamelo (R)
Antidiabetic
- - ------------
Chlorpropamide Diabinese (R)
Glipizide Glucotrol (R)
*Glyburide Glynase (R)
Pres-Tab (R)
Tolazamide Tolinase (R)
Tolbutamide Orinase (R)
Antidiarrheal
- - -------------
Diphenoxylate HCl & Atropine Sulfate Lomotil (R)
Loperamide HCl Imodium (R)
Antiemetic
- - ----------
Prochlorperazine Maleate Compazine (R)
Antigout
- - --------
Allopurinol Zyloprim (R)
Antihypertensive
- - ----------------
Amiloride HCl & Hydrochlorothiazide Moduretic (R)
Captopril Capoten (R)
Captopril and Hydrochlorothiazide Capozide (R)
Clonidine Catapres (R)
Guanfacine HCl Tenex (R)
Indapamide Lozol (R)
Methyldopa Aldomet (R)
Methyldopa & Hydrochlorothiazide Aldoril (R)
Metoprolol Tartrate Lopressor (R)
Prazosin HCl Minipress (R)
Propranolol HCl Inderal (R)
Propranolol HCl & Hydrochlorothiazide Inderide (R)
Triamterene and Hydrochlorothiazide Dyazide (R)
Triamterene and Hydrochlorothiazide MAXZIDE (R)-25MG
MAXZIDE (R)
Antilipemic
- - -----------
Gemfibrozil Lopid (R)
Antineoplastic
- - --------------
Methotrexate Methotrexate (R)
Rheumatrex (R)
Antipsychotic
- - -------------
Fluphenazine HCl Prolixin (R)
Haloperidol Haldol (R)
Thioridazine HCl Mellaril (R)
Thiothixene Navane (R)
Antiviral
- - ---------
Acyclovir (Capsules) Zovirax (R)
*Acyclovir Zovirax (R)
Generic Name Trade Name
- - ------------ ----------
Anxiolytic
- - ----------
Clorazepate Dipotassium Tranxene (R)
Beta Blocker
- - ------------
Acebutolol HCl Sectral (R)
Pindolol Visken (R)
Timolol Maleate Blocadren (R)
Beta Blocker with Diuretic
- - -----------------------------
Atenolol and Chlorthalidone Tenoretic (R)
Bronchial Dilator
- - -----------------
Albuterol Proventil (R)
Ventolin (R)
Calcium Channel Blocker
- - ------------------------
Diltiazem HCl Cardizem (R)
Diltiazem HCl ER Cardizem SR (R)
Diltiazem HCl ER Dilacor XR (R)
Nicardipine Cardene (R)
Verapamil HCl ER Isoptin (R) SR
Diuretic
- - --------
Bumetanide Bumex (R)
Chlorothiazide Diuril (R)
Chlorthalidone Hygroton (R)
Furosemide Lasix (R)
Methyclothiazide Enduron (R)
Spironolactone Aldactone (R)
Spironolactone & Hydrochlorothiazide Aldactazide (R)
H2 Antagonist
- - -------------
Cimetidine Tagamet (R)
Ranitidine HCl Zantac (R)
Hemorrheologic Agent
- - ---------------------
Pentoxifylline ER Trental (R)
Hypnotic Agent
Flurazepam HCl Dalmane (R)
Temazepam Restoril (R)
Laxative
- - --------
Lactulose Solution Chronulac (R)
Muscle Relaxant
- - ----------------
Cyclobenzaprine HCl Flexeril (R)
*Orphenadrine Citrate ER Norflex TM
Skeletal Muscle Relaxant
- - ------------------------
*Orphenadrine Citrate,Aspirin and Caffeine Norgesi TM
Norgesic TM Forte
Uricosuric
- - ----------
Probenecid Benemid (R)
* Indicates fiscal 1999 introduction
-18-
<PAGE>
Selected Financial Data
Mylan Laboratories Inc.
<TABLE>
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Year ended March 31, 1999 1998 1997 1996 1995 1994 1993 1992
Total revenues $721,123 $555,423 $440,192 $392,860 $396,120 $251,773 $211,964 $ 131,936
Net earnings $115,409 $100,777 $ 63,127 $102,325 $120,869 $ 73,067 $ 70,621 $ 40,114
Earnings per common share-basic $ .92 $ .83 $ .52 $ .86 $ 1.02 $ .62 $ .61 $ .35
Earnings per common share-diluted $ .91 $ .82 $ .51 $ .85 $ 1.01 $ .61 $ .60 $ .35
Shares used in computation-basic 125,584 122,094 121,926 119,530 118,963 118,423 115,651 114,726
Shares used in computation-diluted 127,156 123,043 122,727 120,706 119,912 119,502 116,986 115,927
At year end
Working capital $486,598 $379,726 $323,942 $351,536 $296,990 $197,164 $159,748 $ 106,222
Total assets $1,206,661 $847,753 $777,580 $692,009 $546,201 $403,325 $351,105 $ 226,720
Long-term obligations $ 26,827 $ 26,218 $ 32,593 $ 18,002 $ 7,122 $ 4,609 $ 5,125 $ 3,600
Shareholders' equity $1,059,905 $744,465 $659,740 $616,441 $482,728 $379,969 $295,972 $ 203,452
Book value per share-diluted $ 8.34 $ 6.05 $ 5.38 $ 5.11 $ 4.03 $ 3.18 $ 2.53 $ 1.76
</TABLE>
Numbers in thousands except per share amounts.
From June 1990 through July 1992 the Company had a quarterly dividend program
totaling $.067 per share per year. From October 1992 to July 1993 the Company
had a quarterly dividend program totaling $.08 per share per year. From October
1993 to July 1994 the Company had a quarterly dividend program totaling $.107
per share per year. From October 1994 to July 1995 the Company had a quarterly
dividend program totaling $.133 per share per year. Since October 1995 the
Company has had a quarterly dividend program totaling $.16 per share per year.
In addition, the Company paid a special one-time dividend of $.067 per share on
January 13, 1995. The above financial data gives retroactive effect to the
two-for-one stock split effective August 1, 1992 and the three-for-two stock
split effective August 15, 1995.
-21-
<PAGE>
Management's Discussion and Analysis of Operations and Financial Position
Mylan Laboratories Inc.
Overview
Mylan Laboratories Inc. ("the Company" or "Mylan") recorded net earnings of
$115.4 million for the year ended March 31, 1999, despite recording $29.0
million in charges for acquired in-process research and development during the
year. This represents a 14% increase over net earnings for fiscal 1998 of $100.8
million. Fiscal 1997 net earnings were $63.1 million.
The favorable results of the past two years are indicative of both the
contin-uing evolution of the Company marked by the expansion of the Company's
branded presence and the Company's historical leading role in the generic
pharmaceutical industry.
Historically, earnings from new generic product approvals and increased
generic volume more than offset the loss in net earnings resulting from price
deterioration in the generic market. Beginning in fiscal 1996, however, an
increasingly difficult regulatory environment was compounded by a new wave of
patent litigation by branded pharmaceutical companies under the Drug Price
Competition and Patent Term Restoration Act of 1984 (the "Hatch-Waxman Act").
These two factors significantly increased the cost of bringing new generic
products to market and have in many cases diminished the eventual commercial
success of new products by delaying their introduction.
Against this backdrop, the Company decided to accelerate its planned
expansion into the branded markets to meet long-term corporate objectives.
Additionally, despite a promising pipeline of products in development,
management determined the Company would need to further investigate innovative
strategic alliances aimed at expanding both its branded and generic product
lines.
Accordingly, the Company entered into several strategic alliance
relationships in the past two years, some of which resulted in the introduction
of new generic products, including Ranitidine in fiscal 1998 and Orphenadrine
Citrate ER in fiscal 1999, and some of which have broadened the Company's
growing pipeline of products pending FDA approval. In addition, the Company's
acquisition of Penederm Inc. in October of 1998, significantly broadened the
Company's branded capabilities in terms of sales force, existing product line
and branded product pipeline.
In addition to the uncertainty of new product approvals, price
deterioration during fiscal 1996 and 1997 was more severe than at any other time
in the Company's history. The Company estimates that price deterioration in the
generic industry reduced net earnings by approximately $55 million in fiscal
1996 and $75 million in fiscal 1997. Accordingly, the Company recognized that
action, in addition to the above mentioned efforts, needed to be considered.
After an extensive evaluation of its operations, the Company determined that
changes in Mylan's generic pricing practices were in order.
In the second half of fiscal 1998, the Company raised prices on seven
generic products. During fiscal 1999, the Company raised prices on 22 additional
products. The Company estimates that the price increases accounted for $25
million of the increase in net earnings from fiscal 1997 to fiscal 1998 and $71
million of the increase in net earnings from fiscal 1998 to fiscal 1999.
In December 1998, actions were commenced by the Federal Trade Commission
("FTC") in connection with two products, Clorazepate and Lorazepam, each of
which were included in the Company's fiscal 1998 price increases. At issue in
the FTC litigation are contracts executed in 1997 between the Company and its
raw material supplier for these products. The FTC claims that the exclusivity
provisions of these contracts violate antitrust laws. These exclusivity
provisions have been rescinded.
The two products under FTC investigation combined for approximately 9%
of the Company's consolidated net sales in fiscal 1998 and 21% in fiscal 1999.
Since June 1998, the Company has seen price deterioration on both of these
-22-
<PAGE>
Management's Discussion and Analysis of Operations and Financial Position
Mylan Laboratories Inc.
products and expects to see continued price deterioration in the future.
Additionally, the Company has been informed that significantly higher prices
will be charged by the supplier for future purchases of the raw materials.
Accordingly, the Company expects that net sales and resulting gross margin for
these products in the fiscal year ending March 31, 2000 will be less than that
recognized in the fiscal year ended March 31, 1999. See "Forward Looking
Statements."
The Company intends to continue to work closely with its customers and
suppliers to ensure that Mylan's full line of generic products continues to be
available to the American public as a cost effective alternative to the
innovator products.
Results of Operations
Net Sales and Gross Margin
The following table outlines net sales, gross margin (net sales less cost of
sales) and the corresponding change from the previous year:(dollars in millions)
Year ended Net Sales Gross Margin Gross Margin
March 31, Dollars Change Dollars Change as % of Sales
1999 $721.1 36% $384.3 60% 53%
1998 528.6 20% 240.3 33% 45%
1997 440.2 12% 180.5 -8% 41%
Generic products represented 88% of consolidated net sales in fiscal
1999, 90% in fiscal 1998 and 87% in fiscal 1997. Accordingly, the changes in net
sales, gross margin and gross margin as a percent of net sales are primarily
indicative of the highly competitive nature of the generic pharmaceutical
industry, the Company's history of obtaining new product approvals and the
impact of price increases and strategic alliances on certain products.
With regard to the Company's generic product line, nine products were
added in fiscal 1997 accounting for $34.1 million in net sales in fiscal 1997
and 13 products were added in fiscal 1998 with aggregate net sales of $61.5
million in fiscal 1998. In fiscal 1999 the Company added nine products with
aggregate net sales of $37.1 million. Included in the fiscal 1999 new products
is Glyburide, a product for which the Company had received an approval from the
FDA and begun marketing in fiscal 1997, but was required to suspend commercial
shipments pending the outcome of certain patent related issues.
Two of the fiscal 1998 new products, Ranitidine and Acyclovir, and two
of the fiscal 1999 new products, Orphenidrine Citrate ER and Orphenadrine
Citrate, Aspirin and Caffeine, are manufactured by other companies and
distributed by the Company under distribution arrangements. Under the terms of
the distribution arrangement on Ranitidine, the Company, in 1998, recognized
$26.8 million recorded under the caption "Other revenues" (See note N to the
consolidated financial statements).
The Company estimates that price deterioration in the generic industry
resulted in reductions in net sales and gross margins of approximately $104
million in fiscal 1997, $32 million in fiscal 1998 and $39 million in fiscal
1999. Selective price increases increased net sales by $47 million and gross
margins by $37 million in fiscal 1998 and increased net sales by $130 million
and gross margins by $109 million in fiscal 1999.
As described under "Overview," the Company has experienced price
deterioration on certain significant generic products on which it increased
prices and anticipates that it will experience further price deterioration on
these and other products in the future. Accordingly, net sales and gross margin
percentages realized in fiscal 1999 are not necessarily indicative of future
results.
-23-
<PAGE>
Management's Discussion and Analysis of Operations and Financial Position
Mylan Laboratories Inc.
Total unit volume of generic product shipments, excluding unit dose
shipments, increased by 18% in fiscal 1997, 8% in fiscal 1998 and 10% in fiscal
1999. The higher levels of volume create manufacturing efficiencies which were
realized in each of the three past fiscal years.
Net sales for the Company's branded segment declined from fiscal 1997 to
fiscal 1998 as a result of a realignment of the sales force effort away from the
institutional wound care products which have seen continual price deterioration
and towards physician based products including MAXZIDERegistration Mark,
NITREKRegistration Mark and ClorpresTM. These efforts, coupled with the addition
of ZagamRegistration Mark and SulfamylonRegistration Mark Powder provided for a
25% increase in net sales and gross profit in fiscal 1999 for the Company's
Bertek Pharmaceuticals Inc. Division.
Continued growth in the branded segment is a primary objective for the
Company. Accordingly, on October 2, 1998, the Company completed its acquisition
of Penederm Inc. a Foster City, California corporation which develops and
markets patented topical prescription products. Sales of Penederm products
during the six months post acquisition were approximately $17 million. The
Company has begun to combine the marketing efforts of the Penederm and Bertek
sales forces and anticipates continued improvements in the branded segment
throughout fiscal 2000. The Company also plans to continue to examine external
growth opportunities in the branded arena as internal research and development
projects for branded products continue on their paths towards commercialization.
Research and Development
Research and development expenditures were $61.8 million in fiscal 1999,
$46.3 million in fiscal 1998 and $42.6 million in fiscal 1997. These amounts
represent approximately 9% of net sales in fiscal 1999 and 1998 and 10% in
fiscal 1997.
The following table outlines the approximate allocation of research and
development expenditures: (dollars in millions)
Year ended March 31, 1999 1998 1997
Generic related projects $25.7 $22.0 $20.5
Innovative compound projects 29.2 18.4 16.1
Transdermal patch related 6.9 5.9 6.0
During fiscal 1999, the Company entered into an agreement with Genpharm
Inc. to co-develop 15 branded and generic products. Charges related to this
agreement have been allocated evenly to generic and innovative compound
projects. This expenditure represents a majority of the increase in generic
related expenditures.
In addition to half of the charges relating to the Genpharm agreement,
fiscal 1999 expenditures for innovative compound projects include $2.8 million
of expenditures incurred by Penederm subsequent to the date of acquisition and
approximately $10.0 million in accrued funding obligations resulting from an
arbitration award relating to VivoRx (see note S to the consolidated financial
statements). Charges related to the Company's funding of VivoRx in fiscal 1998
were $6.3 million and in fiscal 1997 were $7.8 million.
Under the terms of the arbitration award, the Company has elected to
terminate the licensing arrangement with VivoRx, and will be entitled to recover
approximately $18.0 million from VivoRx through five annual installment payments
commencing in October 2000.
-24-
<PAGE>
Management's Discussion and Analysis of Operations and Financial Position
Mylan Laboratories Inc.
Acquired In-Process Research and Development
In connection with its acquisition of Penederm Inc. in October 1998, the Company
allocated $29.0 million of the purchase price to in-process research and
development. (See note B to the consolidated financial statements.)
Selling and Administrative
Selling and administrative expenses were $125.0 million in fiscal 1999, $96.7
million in fiscal 1998 and $79.9 million in fiscal 1997. These amounts represent
17% of net sales in fiscal 1999 and 18% of net sales for both fiscal 1998 and
fiscal 1997.
The following table identifies the major components of selling and
adminis-trative expenses: (dollars in millions)
Year ended March 31, 1999 1998 1997
Sales and Marketing Expenses:
Generic:
Payroll and related $4.9 $4.5 $4.3
Advertising and promotions 12.7 16.3 3.2
Branded:
Payroll and related 12.8 9.4 8.0
Advertising and promotions 9.2 4.7 3.0
Other sales and marketing 9.9 8.4 9.2
Total Sales and Marketing Expenses $49.5 $43.3 $27.7
Administrative Expenses:
Payroll and related $27.5 $21.9 $19.0
Legal and professional fees 22.2 12.0 6.8
Goodwill amortization 4.0 1.6 1.6
Other administrative 21.8 17.9 24.8
Total Administrative Expenses $75.5 $53.4 $52.2
The significant change in generic advertising and promotions from fiscal
1997 to fiscal 1998 relates primarily to costs associated with the launch of new
generic products including Ranitidine. Such costs included payments of stocking
fees to customers to assist in the conversion and promotion of the new generic
products. Similar programs of lesser magnitude were provided in fiscal 1999. In
prior years such costs were insignificant.
The majority of the increases in branded and other sales and marketing
expenses from fiscal 1998 to fiscal 1999 relate to Penederm, which incurred $6.9
million of expenses in the second half of fiscal 1999.
Administrative payroll and related expenses increased from fiscal 1998
to fiscal 1999 primarily as a result of expansion of corporate infrastructure
and from the addition of Penederm.
Legal and professional fees relating to patent issues were approximately
$6.0 million in fiscal 1999, $7.2 million in fiscal 1998 and $1.7 million in
fiscal 1997. The significant increase in total legal and professional fees from
fiscal 1998 to fiscal 1999 is related principally to antitrust matters and the
VivoRx litigation.
Equity in Earnings of Somerset
Equity in earnings of Somerset was $5.5 million in fiscal 1999, $10.3 million in
fiscal 1998 and $18.8 million in fiscal 1997. Somerset's contribution to the
Company's net earnings per share was $.04 in fiscal 1999, $.07 in fiscal 1998
and $.14 in fiscal 1997.
Somerset continues research efforts to discover alternative indications
for EldeprylRegistration Mark and the development of other compounds. Unless
such new indications or compounds are approved for commercialization the impact
of generic competition will continue to adversely affect Somerset's contribution
to the Company's net earnings.
-25-
<PAGE>
Management's Discussion and Analysis of Operations and Financial Position
Mylan Laboratories Inc.
Other Income
Other income was $18.3 million in fiscal 1999, $14.0 million in fiscal 1998 and
$10.4 million in fiscal 1997. These amounts are derived principally from
investment earnings and gains and losses on the sale of fixed assets net of
estimated provisions (approximating $12.5 million and $2.5 million in 1999 and
1998 respectively) for adjustments to the carrying value of Other assets,
principally related to investments in strategic alliances and non-publicly
traded companies, including VivoRx.
Income Taxes
The effective tax rate for fiscal 1999 was 40% compared to 32% in fiscal 1998
and 28% in fiscal 1997. Approximately 5% of the fiscal 1999 rate is a result of
the $29 million charge for acquired in-process research and development which is
not deductible for tax purposes. The remainder of the increase in both fiscal
1999 and fiscal 1998 is attributable to increased domestic taxable income
subject to full federal and state taxation.
During fiscal 1998, the Company reached a negotiated settlement with the
Internal Revenue Service regarding audits of the Company's income tax returns
for the years 1992 through 1996. As part of the settlement, the Company agreed
to change the method employed for determining taxable income of its Puerto Rican
operations from the cost sharing method to the profit-split method for all years
after 1996.
Changes in the Federal Tax Code enacted in 1993 reduced tax credits
previously available for operating in Puerto Rico by 50% in fiscal 1997, 55% in
fiscal 1998 and 60% in fiscal 1999. Under current tax law, the amount of income
subject to the Puerto Rican tax credit will be limited for a period of seven
years before complete termination of the credits.
Liquidity and Capital Resources
In fiscal 1999, the Company surpassed the billion-dollar plateau in total assets
and shareholders' equity. Total assets are $1,206.7 million at March 31, 1999
compared to $847.8 million at March 31, 1998. Working capital increased from
$379.7 million in 1998 to $486.6 million in 1999 and the ratio of current assets
to current liabilities decreased from 6.3 to 1 to 6.0 to 1.
Net cash provided from operating activities was $163.4 million in 1999,
$52.7 million in 1998 and $46.5 million in 1997. The primary reasons for the
increase in 1999 were improved operating results and inventory management. Other
contributing factors were the timing of tax payments and collection of accounts
receivable. The increase in operating cash flows also out paced net earnings
growth in 1999 as a result of higher non-cash expense items, including the
increase in allowances on accounts receivable and acquired in-process research
and development.
The Company completed several major capital projects in 1999 that were
started in prior years while continuing to expand its facilities in Morgantown,
West Virginia. The Company's net investment in property, plant and equipment was
$16.7 million in 1999, $28.9 million in 1998 and $26.9 million in 1997. The
expansion at the Morgantown location includes additional manufacturing capacity
and a sales and administrative building. All capital expenditures have been made
with the general funds of the Company and without any bank financing.
In 1999, the Company implemented cash management initiatives by
investing more funds into marketable securities, accounting for the increase in
cash used for investing activities. Generally these funds are invested in
short-term government and corporate securities.
Payments on long-term obligations include obligations assumed in
connection with the acquisition of UDL and installment payments made on certain
product acquisitions. The Company paid cash dividends of $.16 per share in 1999,
1998 and 1997 totaling $58.8 million.
-26-
<PAGE>
Management's Discussion and Analysis of Operations and Financial Position
Mylan Laboratories Inc.
The Company's current cash position will not necessarily be indicative
of its position in future periods. As described under "Overview," the Company
has experienced price deterioration on certain significant generic equivalent
products on which it increased prices and anticipates that it will experience
further price deterioration on these and other products in the future, which
could impact future cash flows. In addition, the Company expects to incur
significant legal fees and costs in defending against the various lawsuits
referenced under "Overview" and described under Item 3 of the Company's Annual
Report on Form 10-K for the year ended March 31, 1999, which could also impact
future cash flows. See also "Forward Looking Statements."
Year 2000
The Company has completed a review of its critical information technology ("IT")
and non-IT operating systems for Year 2000 ("Y2K") compliance. Y2K compliance
refers to the issue of systems and equipment having date sensitive components
being able to recognize the year 2000. On the basis of this review and the
processes described below, management believes that the costs of remediation and
potential losses related to Y2K issues are unlikely to have a material effect on
the Company's financial position, results of operations or cash flows.
In assessing potential Y2K issues, the Company has taken or is taking
the following steps to address its IT and non-IT operating systems:
-Formed a project team across functional departments to complete a
review and identify nonconforming systems.
-Communicated to employees throughout the Company to increase
awareness of issues and activate the identification process.
-Identified critical IT and non-IT nonconforming operating systems and
developed a plan to bring these systems into compliance.
-Established a testing program to ensure that such systems are
compliant.
-Corresponded with customers, vendors, service suppliers and financial
institutions to verify their readiness.
-Developed contingency plans where practical in the event of system
failures.
Because of the continued growth of the Company over the last several
years and prior to the formation of the project team, the Company initiated
major system conversions to accommodate the physical expansion and increased
transaction volume associated with this growth. Many factors were considered
during the selection process. While Y2K compliance was one of the factors
considered, other factors were equally and significantly more important. Any new
systems selected were expected to be and are believed to be Y2K compliant.
The Company has recently completed the system conversions for all major
operating and financial systems. All such systems have been certified by the
vendor to be Y2K compliant. The Company has substantially completed its own
testing on these systems and verified their Y2K compliance.
Due to the recent independent upgrades and replacements of its computer
systems to accommodate its growth, the Company has not been required to spend,
nor does it anticipate spending, significant incremental funds to become Y2K
compliant. The funds for system conversions have been financed through operating
revenue of the Company. The Company has neither delayed, nor anticipates
delaying, any significant information system projects prior to the year 2000.
The project team continues to evaluate and update contingency plans.
These plans are developed based on correspondence with customers, vendors, raw
material suppliers, service suppliers and financial institutions regarding the
status of their Y2K readiness and the results of testing performed on the
Company's internal systems. With the testing of the Company's own systems
substantially complete, more emphasis will be placed on obtaining and verifying
third party responses. Contingency plans will evolve and change with each
favorable or unfavorable response. As part of this process and due to the
critical nature of the Company's products, the Company has also initiated steps
to monitor customers' orders and buying patterns. The Company has taken these
steps to ensure the availability of its products to all its customers as the
millennium approaches.
-27-
<PAGE>
Management's Discussion and Analysis of Operations and Financial Position
Mylan Laboratories Inc.
While the project team continues to develop contingency plans for the more
likely scenarios of possible business interruptions, there can be no assurance
that the project team will identify and develop successful contingency plans for
all of the business interruptions that could possibly occur.
Management believes that the Company has acted with appropriate
diligence to address potential Y2K issues. The Company is, however, dependent on
third parties, such as its customers, vendors, raw material suppliers, service
suppliers which include energy, water, communication and transportation and
financial institutions, to make their own systems Y2K compliant. If these
entities fail to remedy their Y2K issues, the Company could potentially suffer
interruptions in its business operations. These interruptions could potentially
delay the Company in its manufacturing or distribution of some or all its
products for an undeterminable amount of time. In addition, the Company could
experience the corruption of data in its own internal information systems. Such
corruption could lead to temporary interruptions in certain isolated business
operations. These interruptions may or may not lead to an adverse impact on the
Company's overall business operations.
Other Matters
The Financial Accounting Standards Board issued Statement of Financial
Accounting Standards No.133, "Accounting for Derivative Instruments and Hedging
Activities" ("SFAS No. 133"). This statement is effective for fiscal years
beginning after June 15, 2000. The Company is currently evaluating the impact
that SFAS No. 133 will have on its financial position and results of operations.
Market Risk
The Company is exposed to market risk primarily from changes in market values on
its investments in marketable debt and equity securities, including marketable
securities owned indirectly through certain pooled asset funds. Market prices on
debt securities generally bear an inverse relationship to changes in interest
rates. The Company also invests in overnight deposits and money market funds and
marketable securities with maturities of less than three months. These
instruments are classified as cash or cash equivalents for financial reporting
purposes and have minimal or no interest rate risk. The Company also invests in
non-public securities, often in consideration of its strategic interests. The
Company does not consider these investments to be market risk sensitive.
The Company attempts to mitigate its exposure to market risk by
assessing the relative proportion of its investments in cash and cash
equivalents and the relatively stable and risk minimized returns available on
such investments with the risks attendant to its investments in debt and equity
securities. The Company's objective in managing its exposure to changes in the
market value of its investments in debt and equity securities is to balance the
risk of the impact of such changes on earnings and cash flows with the Company's
expectations for investment returns. The Company's pooled asset funds and
certain of its other investments in debt and equity securities are managed by
professional portfolio managers. The Company was not a party to any forward or
derivative option contract related to interest rates or equity security prices
during fiscal 1999.
The fair market value of the debt securities held by the Company at
March 31, 1999 was $60.2 million, of which $42.4 million had maturities of less
than one year (the market values of which are generally less sensitive to
interest rate fluctuations than is the case with longer term debt instruments).
The fair market value of the equity securities held by the Company at March 31,
1999 was $48.9 million. Such investments collectively represent 9% of the
Company's total assets as of March 31, 1999 and 36% of the aggregate value of
debt and equity securities and cash and cash equivalents held by the Company at
such date. Assuming an instantaneous 10% decrease in the market values of the
Company's debt and equity securities, the change in the aggregate fair market
value of these securities would be $10.9 million.
Forward Looking Statements
Various statements in this Report state or suggest that the Company expects to
increase revenues and to continue to be profitable in the future by employing
various strategies which include continuing to seek, among other things, to
introduce new lines of generic equivalent products, to enter into alliances with
other
-28-
<PAGE>
Management's Discussion and Analysis of Operations and Financial Position
Mylan Laboratories Inc.
manufacturers, to strengthen the development of branded products and to increase
prices on select generic equivalent products in its line. These are
forward-looking statements. The Company's actual results could differ materially
from those projected or suggested in any forward-looking statement due to
various important factors, including, but not limited to, the following:
The Company's results of operations depend to a significant extent on
its ability to develop and bring to market new generic equivalent products.
Generally, following the expiration of patents and other FDA exclusivity
periods, the first manufacturers to bring a generic equivalent to the market
achieve higher revenues and gross profits than competitors that subsequently
enter the market. As competing products enter the market, prices, sales volume
and profit margins of the first generic equivalents decline significantly.
Furthermore, since 1997, the Company has increased prices on selected older
generic equivalent products, including in some cases generic equivalents which
were largely abandoned by competitors, which has encouraged other generic
manufacturers to reenter the market. These conditions have also resulted or are
expected to result in price deterioration on these products.
In addition to suffering price deterioration on its generic equivalent
products generally, the Company's results of operation for fiscal 1999 continued
to be impacted by delays in its ability to introduce new generic equivalent
products due to litigation initiated by branded manufacturers under the
Hatch-Waxman Act to extend the exclusivity periods of drugs on which patents
were expiring. The failure of Congress or the courts to address the present
abuses of the Hatch-Waxman Act could diminish the comme rcial success of new
products introduced by the Company, resulting in both lower revenues and gross
margins.
The Company is seeking to strengthen its development of branded
products. Obtaining approval from the FDA to market new (branded) pharmaceutical
products in the United States is a lengthy, complex and expensive process.
Products which appear promising in the research laboratories may fail to survive
the testing phase due to ineffectiveness or as a result of unforeseen side
effects. Even if the Company is successful in obtaining approval for new
products, no assurance can be given that such products will be accepted in the
medical community as being as effective as alternative forms of treatment for
indicated conditions.
The Company's principal customers include wholesale drug distributors
and major drug store chains. A continuation of the consolidation, which has been
experienced in these pharmaceutical distribution networks in recent years, is
likely to result in an increase in pricing pressures on pharmaceutical
manufacturers.
As described under Item 3 of the Company's Annual Report on Form 10-K
for the year ended March 31, 1999, the Company is involved in numerous
lawsuits, including anti-trust and anti-competition litigation brought by the
Federal Trade Commission, the Attorneys General for 33 states and numerous
private litigants, as well as a class action lawsuit alleging that the Company
violated federal securities laws by failing to disclose the alleged
monopolization of certain raw materials used to manufacture drugs. An
unfavorable outcome in these suits could have a potentially adverse effect on
the Company's financial position and results of operation or, in certain
circumstances, the manner in which the Company is permitted to conduct its
future operations.
The statements under "Year 2000" of "Management's Discussion and
Analysis of Financial Condition and Results of Operations" which express the
Company's belief that Y2K problems will not have a material adverse effect on
the Company may also be forward-looking statements. Factors which could cause
the Company to be unable to avoid any material Y2K problems include the failure
of its Y2K project team to identify latent or other non-compliant codes or
technologies, the failure of any of the customers, vendors, service suppliers or
financial institutions with which the Company deals to address their own Y2K
problems or the ineffectiveness of any contingency plans put in place by the
Company to mitigate the effects of interruptions in its businesses due to Y2K
problems.
See also the discussion of the Company's business, including the
regulatory environment, customers, markets and competitive conditions included
in Item 1 of the Company's Annual Report on Form 10-K for the year ended March
31, 1999.
-29-
<PAGE>
Consolidated Balance Sheets
Mylan Laboratories Inc.
(dollars in thousands except per share data)
March 31 1999 1998
Assets
Current assets
Cash and cash equivalents $ 189,849 $ 103,756
Marketable securities 69,872 41,941
Accounts receivable 148,896 136,864
Inventories 136,493 146,041
Deferred income tax benefit 18,199 7,845
Prepaid and refundable income taxes 88 7,946
Other current assets 19,562 6,679
---------- ----------
Total current assets 582,959 451,072
Property, plant and equipment - net
of accumulated depreciation 154,636 151,412
Intangible assets - net of accumulated
amortization 336,003 128,745
Other assets 98,949 86,803
Investment in and advances to Somerset 34,114 29,721
---------- ----------
Total assets $ 1,206,661 $ 847,753
See notes to consolidated financial statements.
-30-
<PAGE>
Consolidated Balance Sheets
Mylan Laboratories Inc.
(dollars in thousands except per share data)
March 31, 1999 1998
Liabilities and shareholders' equity
Current liabilities
Trade accounts payable $ 12,142 $ 15,957
Current portion of long-term obligations 16,941 8,477
Income taxes payable 821 5,377
Other current liabilities 61,279 36,635
Cash dividend payable 5,178 4,900
--------- ---------
Total current liabilities 96,361 71,346
Long-term obligations 26,827 26,218
Deferred income tax liability 23,568 5,724
Shareholders' equity
Preferred stock, par value $.50 per share, - -
authorized 5,000,000 shares, issued
and outstanding - none
Common stock, par value $.50 per share,
authorized 300,000,000 shares, issued
129,968,514 at March 31, 1999 and
123,050,172 at March 31, 1998 64,984 61,525
Additional paid-in capital 311,995 92,405
Retained earnings 690,003 594,847
Accumulated other comprehensive earnings 1,105 1,570
--------- ---------
1,068,087 750,347
Less treasury stock at cost - 888,578
shares at March 31, 1999 and
849,858 shares at
March 31, 1998 8,182 5,882
--------- ---------
Total shareholders' equity 1,059,905 744,465
Total liabilities and shareholders'
equity $ 1,206,661 $ 847,753
============ ==========
-31-
<PAGE>
Consolidated Statements of Earnings
Mylan Laboratories Inc.
(dollars in thousands except per share data)
Year ended March 31, 1999 1998 1997
Net sales $721,123 $ 528,601 $440,192
Other revenues - 26,822 -
-------- ---------- --------
Total revenues 721,123 555,423 440,192
Cost and expenses
Cost of sales 336,846 288,290 259,666
Research and development 61,843 46,278 42,633
Acquired in-process research and development 29,000 - -
Selling and administrative 124,964 96,708 79,948
-------- ---------- --------
552,653 431,276 382,247
Equity in earnings of Somerset 5,482 10,282 18,342
Other Income 18,342 13,960 10,436
--------- ---------- -------
Earnings before income taxes 192,294 148,389 87,195
Income taxes 76,885 47,612 24,068
--------- ---------- -------
Net earnings $115,409 $ 100,777 $63,127
========= ========== =======
Earnings per common share
Basic $ .92 $ .83 $ .52
Diluted $ .91 $ .82 $ .51
Weighted average common shares outstanding
Basic 125,584,000 122,094,000 121,926,000
Diluted 127,156,000 123,043,000 122,727,000
See notes to consolidated financial statements.
-32-
<PAGE>
Consolidated Statements of Shareholders' Equity and Comprehensive Earnings
Mylan Laboratories Inc.
<TABLE>
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C>
Accumulated Other
(dollars in thousands except Common Stock Treasury Stock Additional Comprehensive Total
--------------------- ------------------ ---------- Retained Earnings Shareholders' Comprehensive
per share data) Shares Amount Shares Amount Paid-In Earnings (Loss) Equity Earnings
Capital
- - ------------------------------------------------------------------------------------------------------------------------------------
April 1, 1996 122,524,789 $ 61,262 (694,950) ($2,528) $85,996 $ 470,136 $1,575 $ 616,441 -
Net earnings - - - - - 63,127 - 63,127 $63,127
Net unrealized loss on
marketable securities - - - - - - (2,522) (2,522) (2,522)
Stock options exercised 290,167 145 (75,000) (1,266) 3,266 - - 2,145 -
Reissuance of treasury stock - - 17,000 62 - - - 62 -
Cash dividend $.16 per share - - - - - (19,513) - (19,513) -
----------- --------- -------- -------- ------- ----------- ------- ----------- --------
March 31, 1997 122,814,956 61,407 (752,950) (3,732) 89,262 513,750 (947) 659,740 60,605
Net earnings - - - - - 100,777 - 100,777 100,777
Net unrealized gain on
marketable securities - - - - - - 2,517 2,517 2,517
Stock options exercised 235,216 118 (513) (12) 3,143 (141) - 3,108 -
Purchase of treasury stock - - (144,900) (2,459) - - - (2,459) -
Reissuance of treasury stock - - 48,505 321 - - - 321 -
Cash dividend $.16 per share - - - - - (19,539) - (19,539) -
----------- --------- -------- -------- ------- ----------- ------- ----------- --------
March 31, 1998 123,050,172 61,525 (849,858) (5,882) 92,405 594,847 1,570 744,465 103,294
Net earnings - - - - - 115,409 - 115,409 115,409
Net unrealized loss on
marketable securities - - - - - - (465) (465) (465)
Stock options exercised 1,013,313 507 (85,270) (2,642) 16,916 (141) - 14,640 -
Reissuance of treasury stock - - 46,550 342 - - - 342 -
Cash dividend $.16 per share - - - - - (20,112) - (20,112) -
Penederm acquisition 5,905,029 2,952 - - 202,674 - - 205,626 -
----------- --------- -------- -------- ------- ----------- ------- ----------- --------
March 31, 1999 129,968,514 $ 64,984 (888,578) ($8,182) $311,995 $ 690,003 1,105 $1,059,905 $ 114,944
=========== ========= ======== ======== ======= =========== ======= =========== ========
</TABLE>
See notes to consolidated financial statements.
-33-
<PAGE>
Consolidated Statements of Cash Flows
Mylan Laboratories Inc.
(dollars in thousands except supplemental disclosure)
Year ended March 31, 1999 1998 1997
Cash flows from operating activities
Net earnings $115,409 $ 100,777 $63,127
Adjustments to reconcile net
earnings to net cash provided
from operating activities:
Depreciation and amortization 26,911 21,708 17,347
Deferred income tax (benefit) expense (10,314) (3,207) 47
Equity in earnings of Somerset (5,482) (10,282) (18,814)
Cash received from Somerset 1,089 5,674 20,038
Allowances on accounts receivable 19,300 8,754 2,422
Acquired in-process research and development 29,000 - -
Loss on sale of assets - - 1,171
Other noncash expenses (646) 1,574 290
Changes in operating assets and liabilities:
Accounts receivable (30,411) (30,565) (45,198)
Inventories 11,328 (45,007) (1,495)
Trade accounts payable (4,282) (2,082) 4,000
Income taxes 8,549 (8,949) 773
Other operating assets and liabilities 2,998 14,255 2,829
------- ------ ------
Net cash provided from operating activities 163,449 52,650 46,537
Cash flows from investing activities
Additions to property, plant and equipment (16,736) (28,853) (26,854)
Increase in intangible and other assets (7,915) (7,984) (30,674)
Purchase of investment securities (79,816) (16,785) (23,221)
Proceeds from investment securities 50,151 17,309 18,060
Proceeds from sale of assets - - 3,500
Cash acquired net of acquisition costs 1,396 - -
Net cash used in investing activities (52,920) (36,313) (59,189)
See notes to consolidated financial statements.
-34-
<PAGE>
Consolidated Statements of Cash Flows
Mylan Laboratories Inc.
(dollars in thousands except supplemental disclosure)
Year ended March 31, 1999 1998 1997
Cash flows from financing activities
Payments on long-term obligations $(14,740) $ (19,198) $(19,788)
Cash dividends paid (19,833) (19,525) (19,491)
Repurchase of common stock - (2,459) -
Proceeds from exercise of stock options 10,137 2,445 1,107
-------- ---------- --------
Net cash used in financing activities (24,436) (38,737) (38,172)
-------- ---------- --------
Net increase (decrease) in cash and
cash equivalents 86,093 (22,400) (50,824)
Cash and cash equivalents - beginning
of year 103,756 126,156 176,980
-------- ---------- --------
Cash and cash equivalents - end of year $ 189,849 $103,756 $ 126,156
-------- ---------- --------
Supplemental Disclosure
For purposes of presentation in the statements of cash flows, cash, overnight
deposits and money market funds and marketable securities with original
matu-rities of less than three months have been classified as cash and cash
equivalents.
Cash payments for interest were $1,800,000 in 1999, $3,426,000 in 1998,
and $1,977,000 in 1997. Cash payments for income taxes were $78,650,000 in 1999,
$59,770,000 in 1998, and $23,245,000 in 1997.
Certain stock option transactions result in a reduction of income taxes
payable and a corresponding increase in additional paid in capital. The amounts
for the years ended March 31, 1999, 1998, and 1997 were $4,302,000, $652,000 and
$205,000 respectively.
In consideration for the exercise of stock options, the Company received
and recorded into treasury stock 85,270 shares valued at $2,642,000 in fiscal
1999, 513 shares valued at $12,000 in fiscal 1998, and 75,000 shares valued at
$1,266,000 in fiscal 1997.
During fiscal 1999 the Company acquired all of the outstanding stock of
Penederm (see note B). The purchase price of approximately $207,938,000 was
satisfied principally through the issuance of the Company's common stock.
During fiscal 1999 in connection with product license agreements the
Company recorded intangible assets and the related obligations of $22,300,000 in
excess of amounts paid. In fiscal 1997 the Company recorded intangible assets
and long-term obligations of $49,666,000 in excess of amounts paid related to
the acquisition of MAXZIDE Registration Mark.
-35-
<PAGE>
Notes to Consolidated Financial Statements
Mylan Laboratories Inc.
A. Summary of Significant Accounting Policies 1. Nature of Operations and
Principles of Consolidation The consolidated financial statements include
the accounts of Mylan Laboratories Inc. ("the Company") and its
wholly-owned subsidiaries. All intercompany accounts and transactions have
been eliminated in consolidation. The Company is engaged in the
development, manufacture and distribution of pharmaceutical products for
resale by others. The principal markets for these products are proprietary
and ethical pharmaceutical wholesalers and distributors, drug store chains,
drug manufacturers and public and governmental agencies within the United
States.
2. Marketable Securities
The Company's investments are classified as "available for sale" and are
recorded at market value with net unrealized gains and losses, net of
income taxes, reflected in accumulated other comprehensive earnings in
shareholders' equity. Net gains and losses on sales of securities available
for sale are computed on a specific security basis and included in other
income.
3. Accounts Receivable and Revenue Recognition
The Company recognizes revenue from product sales upon shipment to
customers. Provisions for estimated discounts, rebates, price adjustments,
returns and other adjustments are provided for in the same period as the
related sales are recorded.
Accounts receivable are presented net of provisions which amounted to
$43,584,000 and $23,385,000 at March 31, 1999 and 1998, respectively.
4. Inventories
Inventories are stated at the lower of cost (principally, first-in,
first-out) or market.
5. Property, Plant and Equipment
Property, plant and equipment are stated at cost. Depreciation is provided
in amounts sufficient to relate cost of depreciable assets to operations
over the estimated service lives, principally on a straight-line basis.
6. Intangible Assets
Intangible assets are stated at cost. Amortization is provided for on a
straight-line basis over estimated useful lives not to exceed forty years.
Intangible assets are periodically reviewed to determine recoverability by
comparing carrying value to expected future cash flows.
7. Research and Development
Research and development expenses are charged to operations as incurred.
8. Income Taxes
Income taxes have been provided for using an asset and liability approach
in which deferred income taxes reflect the tax consequences on future years
of events that have already been recognized by the Company in the financial
statements or tax returns. Changes in enacted tax rates or laws will result
in adjustments to the recorded tax assets or liabilities in the period that
the tax law is enacted.
9. Concentrations of Credit Risk
Financial instruments that potentially subject the Company to credit risk
consist principally of interest-bearing investments and accounts
receivable. The Company performs ongoing credit evaluations of its
customers and generally does not require collateral. Three of the Company's
customers accounted for 15%, 14%, and 11% of net sales in fiscal 1999 and
13%, 12%, and 11% of nets sales in fiscal 1998. No single customer
represented more than 10% of net sales in fiscal 1997. At March 31, 1999,
approximately 48% of the accounts receivable balance represented amounts
due from three customers.
The Company invests its excess cash in deposits with major banks and
other high quality short-term liquid money market instruments (commercial
paper, government and government agency notes and bills, etc.). These
investments generally mature within twelve months.
-36-
<PAGE>
Notes to Consolidated Financial Statements
Mylan Laboratories Inc.
10. Earnings per Share
During fiscal 1998 the Company adopted Statement of Financial Accounting
Standards No. 128, "Earnings per Share." This statement establishes
standards for computing and presenting basic and diluted earnings per
share. Basic earnings per share is computed by dividing net earnings by the
weighted average common shares outstanding for the period. Diluted earnings
per share is computed by dividing net earnings by the weighted average
common shares outstanding adjusted for the dilutive effect of options
granted under the Company's stock option plans. Prior periods have been
restated to reflect this new statement.
A reconciliation of diluted earnings per share is as follows: (in
thousands except per share amounts)
March 31, 1999 1998 1997
Net earnings $115,409 $100,777 $ 63,127
Weighted average common shares 125,584 122,094 121,926
Assumed exercise of stock options 1,572 949 801
-------- -------- ---------
Diluted weighted average common shares 127,156 123,043 122,727
Diluted earnings per share $ .91 $ .82 $ .51
11. Accounting Standards
Effective April 1, 1998, the Company adopted the provisions of Statement of
Financial Accounting Standards No. 130, "Reporting Comprehensive Income,"
which establishes standards for recording and disclosing comprehensive
income and its components in the financial statements. Comprehensive income
includes all changes in shareholders' equity except those resulting from
investments by owners and distributions to owners. The Company's
comprehensive earnings are comprised of net earnings and the unrealized
gain and loss on marketable securities, net of income taxes.
In June 1998, the Financial Accounting Standards Board issued
Statement of Financial Accounting Standards No.133, "Accounting for
Derivative Instruments and Hedging Activities" ("SFAS No. 133"). SFAS
No.133 establishes accounting and reporting standards for derivative
instruments, including certain derivatives embedded in other contracts, and
hedging activities. It requires that an entity recognize all derivatives as
either assets or liabilities on the balance sheet at fair value. This
statement is effective for fiscal years beginning after June 15, 2000. The
Company is currently evaluating the impact that SFAS No.133 will have on
its financial position and its results of operations.
12. Use of Estimates in the Preparation of Financial Statements The
preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions
that affect the amounts reported in those financial statements and
accompanying notes. Actual results could differ from those estimates.
13. Reclassification
Certain prior year amounts have been reclassified to conform to the 1999
presentation.
B. Acquisitions
On October 2, 1998, a wholly-owned subsidiary of the Company acquired 100%
of the outstanding stock of Penederm Inc. ("Penederm"). Penederm primarily
develops and markets patented topical prescription products. Penederm
maintains administrative and research and development facilities in Foster
City, California.
The business combination has been accounted for under the purchase
method of accounting. Payment of approximately $207,938,000 was made
principally through the issuance of 5,905,029 shares of the Company's
common stock and the assumption of 877,367 stock options granted prior to
the transaction. Goodwill and various intangible assets acquired total
approximately $193,000,000 and are being amortized on a straight-line basis
over periods not to exceed 20 years.
The Company allocated a portion of the purchase price to in-process
research and development ("IPR&D"). IPR&D represents on going research and
development projects acquired by the Company which have not yet been
approved by the
-37-
<PAGE>
Notes to Consolidated Financial Statements
Mylan Laboratories Inc.
Food and Drug Administration ("FDA") and would have no alternative future
use. The Company used independent professional valuation consultants to
assess and allocate values to IPR&D.
The Company acquired five IPR&D projects of which two were
significant to the IPR&D valuation. One project is for the treatment of
inflammatory fungal conditions while the other project is for a nail
antifungal product. In accessing the value to be allocated to only these
two projects it was estimated that they were 42% complete and would require
approximately $9,100,000 of additional Company funding to complete.
Estimated future cash flows for each project were discounted to their
present value using a rate of 31%. These discounted cash flow projections
were then adjusted by the estimated completion percentage for each project.
The total value allocated to all IPR&D projects was $29,000,000.
At the date of acquisition, the Company believes that the
assumptions used in the valuation process were reasonable. No assurance can
be given, however, that the underlying assumptions used in the valuation of
these projects will be realized. Pharmaceutical product development has
inherent risks in the formulation, manufacture, approval process and
marketplace environment which could affect or prevent each of these
projects from achieving commercial success.
The results of Penederm's operations have been included in the
Company's Consolidated Statement of Earnings from the date of acquisition.
Unaudited pro forma information assuming the acquisition had occurred on
April 1, 1997 is as follows, excluding the one-time charge of the
$29,000,000 relating to acquired IPR&D: (in thousands except per share
amounts)
Year ended March 31, 1999 1998
Total revenues $731,641 $565,378
Net earnings $140,948 $ 85,532
Diluted earnings per common share $ 1.08 $ .66
-------- --------
Diluted weighted average common shares outstanding 130,241 129,075
-------- --------
The pro forma financial information is presented for comparative
purposes only and does not purport to be indicative of the operating
results or financial position that would have occurred had the merger been
consummated at the beginning of the periods presented, nor is such
information necessarily indicative of the future operating results of the
combined company after the merger.
During fiscal 1999, the Company purchased various product and
marketing rights with an aggregate purchase price of $30,300,000. The
purchase agreements require fixed payments and royalties on product sales
in future periods.
C. Inventories
Inventories consist of the following components: (in thousands)
March 31, 1999 1998
Raw materials $57,414 $63,308
Work in process 20,813 27,858
Finished goods 58,266 54,875
-------- --------
$136,493 $146,041
D. Property, Plant and Equipment
Property, plant and equipment consists of the following components:
(in thousands)
March 31, Useful Lives 1999 1998
Land and land improvements - $ 6,583 $ 6,909
Buildings and improvements 20 - 40 86,898 72,893
Machinery and equipment 5 - 10 137,716 122,572
------- -------- --------
Construction in progress - 13,596 23,945
244,793 226,319
Less accumulated depreciation 90,157 74,907
-------- --------
$154,636 $151,412
-38-
<PAGE>
Notes to Consolidated Financial Statements
Mylan Laboratories Inc.
E Investment in and Advances to Somerset
The Company owns 50% of the outstanding common stock of Somerset
Pharmaceuticals, Inc. ("Somerset") and uses the equity method of accounting
for its investment.
Equity in Earnings of Somerset includes the Company's 50% portion of
Somerset's net earnings and expense for amortization of intangible assets
resulting from the acquisition of Somerset. Such intangible assets are
amortized over a 15 year period. Amortization expense amounted to $924,000
in fiscal 1999, 1998, and 1997. Additionally, the Company's charges to
Somerset for management services and product development activities are
included in Equity in Earnings of Somerset. These charges have been
recorded by Somerset as a reduction of its net earnings.
Condensed audited balance sheet information of Somerset is as
follows: (in thousands)
December 31, 1998 1997 1996
Current assets $70,929 $53,973 $45,871
Non-current assets 2,040 3,466 7,006
Current liabilities 16,584 15,660 19,075
Payable to owners 595 1,433 1,621
Condensed audited income statement information of Somerset is as
follows: (in thousands)
Year ended December 31, 1998 1997 1996
Net sales $43,557 $66,956 $101,512
Cost and expenses 19,316 30,055 46,895
Income taxes 9,635 12,924 18,815
------- ------- --------
Net earnings $14,606 $23,977 $35,802
The above information represents 100% of Somerset's operations of
which the Company has a 50% interest.
Somerset's marketing exclusivity for EldeprylRegistration Mark under
the Orphan Drug Act expired on June 6, 1996. Somerset has experienced
increased competition since August 1996, due to the approval of several
generic tablet forms of EldeprylRegistration Mark by the FDA. This has
resulted in a decrease in sales and net earnings since 1996.
In 1997 Somerset was notified by the Internal Revenue Service
("IRS") that it had initiated a challenge related to issues concerning
Somerset's Code Section 936 credit for tax years 1993 through 1995. As of
December 31, 1998, the proposed adjustments by the IRS amounted to
approximately $14,000,000 of additional income tax and interest charges
over amounts accrued, of which 50% would be the Company's share. Management
of Somerset believes it has appropriately claimed the Code Section 936
credit and intends to vigorously defend its position on this matter.
F Marketable Securities
The amortized cost and estimated market values at March 31, 1999 and 1998
are as follows: (in thousands)
Gross Gross
Amortized Unrealized Unrealized Market
March 31, 1999 Cost Gains Losses Value
Debt securities $60,071 $ 303 $187 $ 60,187
Equity securities 8,101 2,144 560 9,685
$68,172 $2,447 $747 $ 69,872
Gross Gross
Amortized Unrealized Unrealized Market
March 31, 1998 Cost Gains Losses Value
Debt securities $28,942 $ 380 $ 32 $ 29,290
Equity securities 10,584 3,852 1,785 12,651
$39,526 $4,232 $1,817 $ 41,941
-39-
<PAGE>
Notes to Consolidated Financial Statements
Mylan Laboratories Inc.
Maturities of debt securities at market value at March 31, 1999 are as
follows: (in thousands)
Mature in one year or less $42,413
Mature after one year through five years 6,152
Mature after five years 11,622
-------
$60,187
Proceeds from sales of marketable securities were $50,151,000, $17,233,000
and $11,369,000 during fiscal 1999, 1998 and 1997. Gross gains of $942,000,
$767,000 and $565,000 and gross losses of $205,000, $82,000, and $271,000,
were realized during fiscal 1999, 1998 and 1997. The cost of investments
sold is determined by the specific identification method.
G. Intangible Assets
Intangible assets consist of the following components: (in thousands)
March 31, Useful Lives 1999 1998
Patents and technologies 10 - 20 $122,985 $ 27,281
License fees and agreements 2 - 12 33,086 7,587
MaxzideRegistration Mark intangibles 25 69,666 69,666
Goodwill 20 - 40 128,480 31,732
Other 5 - 20 28,462 25,719
------- -------- --------
382,679 161,985
Less accumulated amortization 46,676 33,240
-------- --------
$ 336,003 $128,745
The MAXZIDE Registration Mark intangibles relate to trademark, tradedress
and marketing rights. The balance in Other consists principally of an
assembled workforce, non-compete agreements, customer lists and contracts.
Goodwill, patents and technologies and various other intangible assets of
approximately $193,000,000 were acquired in the Penederm transaction.
H. Other Assets
Other assets consist of the following components: (in thousands)
March 31, 1999 1998
Pooled asset funds $46,611 $25,368
Cash surrender value 29,742 26,569
Other investments 22,596 34,866
------- -------
$98,949 $86,803
Pooled asset funds include the Company's interest in various limited
partnership funds which consist of common and preferred stocks, bonds, and
money market funds. Earnings on these investments included under the
caption Other income amounted to $19,530,000, in 1999, $6,572,000, in 1998,
and $1,184,000, in 1997. At March 31, 1999 and 1998 the carrying amounts of
these investments approximated fair value.
Cash surrender value is related to insurance policies on certain
officers and key employees and the value of split dollar life insurance
agreements with certain current and former executive officers of the
Company.
Other investments are comprised principally of investments in
non-publicly traded equity securities and are accounted for under the cost
method. Management periodically reviews the carrying value of these
investments for impairment. The change in other investments from 1998
reflects adjustments made to reduce the carrying value of these investments
to their estimated fair value.
-40-
<PAGE>
Notes to Consolidated Financial Statements
Mylan Laboratories Inc.
I. Other Current Liabilities
Other current liabilities consist of the following components:
(in thousands)
March 31, 1999 1998
Payroll and employee benefit plan accruals $20,672 $16,726
VivoRx funding (See note S) 10,302 3,000
Medicaid 8,305 4,412
Legal and professional 3,811 2,100
Royalties 4,958 6,164
Product license fees 8,802 1,125
Other 4,429 3,108
------- -------
$61,279 $36,635
J. Long-Term Obligations
Long-term obligations include accruals for postretirement compensation
pursuant to agreements with certain key employees and directors of
approximately $13,463,000, and $11,494,000, at March 31, 1999 and 1998.
Under these agreements, benefits are to be paid over periods of 10 to 15
years commencing at retirement.
The Company's obligation on 10.5% senior promissory notes is
$4,000,000, and $5,100,000, at March 31, 1999 and 1998. Future principal
payments on these notes are in amounts ranging from $1,000,000 to
$2,000,000, per year through 2002. At March 31, 1999 and 1998, the Company
was in compliance with all of its debt covenants.
The present value of the Company's obligations for product acquisitions
was $24,605,000 at March 31, 1999 and $16,316,000 at March 31, 1998. Future
payments including minimum royalty payments for these agreements will be
approximately $18,500,000 in fiscal 2000, $2,000,000 in fiscal 2001,
$3,750,000 in fiscal 2002 and $2,000,000 in fiscal 2003.
K. Income Taxes
Income taxes consist of the following components: (in thousands)
Year ended March 31, 1999 1998 1997
Federal
Current $77,546 $45,601 $19,176
Deferred (9,617) (2,993) 68
------- ------- -------
67,929 42,608 19,244
State
Current 9,653 5,218 4,845
Deferred (697) (214) (21)
------- ------- -------
8,956 5,004 4,824
Income taxes $76,885 $47,612 $24,068
-------- -------- -------
Pre-tax earnings $192,294 $148,389 $87,195
-------- -------- -------
Effective tax rate 40.0% 32.1% 27.6%
-------- -------- -------
-41-
<PAGE>
Notes to Consolidated Financial Statements
Mylan Laboratories Inc.
Temporary differences and carryforwards which give rise to the
deferred tax assets and liabilities are as follows: (in thousands)
March 31, 1999 1998
Deferred tax assets:
Employee benefits $ 5,090 $4,397
Intangible assets 3,627 4,080
Asset allowances 17,841 8,230
Inventory 1,069 411
Investments 5,411 4,188
Tax loss carryforwards 18,198 -
Tax credit carryforwards 3,683 -
Other 266 (69)
-------- -------
Total deferred tax assets 55,185 21,237
Deferred tax liabilities:
Plant and equipment 10,373 8,702
Intangible assets 43,675 6,829
Investments 6,506 3,585
-------- -------
Total deferred tax liabilities 60,554 19,116
-------- -------
Deferred tax asset (liability) - net ($5,369) $2,121
-------- -------
Classification in the consolidated balance sheets:
Deferred income tax benefit - current $18,199 $7,845
Deferred income tax liability - non-current 23,568 5,724
-------- -------
Deferred tax asset (liability) - net ($5,369) $2,121
-------- -------
Deferred tax assets relating to net operating loss carryforwards and
R&D tax credit carryforwards were acquired during fiscal 1999 upon the
acquisition of Penederm Inc. Future utilization of these assets is subject
to certain limitations set forth in the Internal Revenue Code. The Company
has approximately $49,000,000 of federal and state tax loss carryforwards
and $3,683,000 of tax credits to offset future taxable income. The loss
carryforwards and tax credits expire in fiscal years 2002 through 2013.
A reconciliation of the statutory tax rate to the effective tax rate
is as follows:
Year ended March 31, 1999 1998 1997
Statutory tax rate 35.0% 35.0% 35.0%
IPR&D 5.3% - -
State income taxes-net 3.1% 2.3% 4.8%
Tax exempt earnings-primarily dividends (1.1%) (2.4%) (6.4%)
Tax credits (2.6%) (3.0%) (5.9%)
Other items 0.3% 0.2% 0.1%
----- ----- -----
Effective tax rate 40.0% 32.1% 27.6%
----- ----- -----
Tax credits result principally from the Company's operations in
Puerto Rico and from qualified research and development expenditures.
State income taxes include provisions for tollgate tax resulting
from the future repatriation of funds from the Company's operation in
Puerto Rico to the United States. Such provisions have been made to the
minimum extent provided under Puerto Rican tax law based on the Company's
intent to reinvest Puerto Rican source earnings in qualifying investments
within Puerto Rico.
The Company's federal tax returns have been audited by the IRS
through March 31, 1996.
-42-
<PAGE>
Notes to Consolidated Financial Statements
Mylan Laboratories Inc.
L. Common Stock
On August 23, 1996, the Company's Board of Directors adopted a Shareholder
Rights Plan ("the Rights Plan"). The Rights Plan was adopted to provide the
Company's Directors with sufficient time to assess and evaluate any
takeover bid, and explore and develop a reasonable response. The Rights
Plan will expire on September 5, 2006 unless a triggering event has
occurred.
M. Commitments
The Company has entered into various contractual agreements, principally
licensing arrangements, whereby the Company has obtained, in exchange for
funding of drug development activities, rights to manufacture and/or
distribute certain drugs, which are presently in various stages of
development. In the event that all projects are successful, milestone
payments totaling $23,375,000, would be made over the next five years.
Approximately ninety-five percent of this total is due upon the filing and
approval of an Abbreviated New Drug Application or New Drug Application
with the FDA.
N. Other Revenues
Under the terms of the Company's supply and distribution agreement with
Genpharm Inc. ("Genpharm") relating to sales of Ranitidine HCL Tablets, the
Company also benefits from an agreement between Genpharm and Novopharm
Limited ("Novopharm"). The Company recognized revenue of $26,822,000, in
fiscal 1998 in connection with the Genpharm Novopharm agreement. Based on
an independent audit, Genpharm initiated a lawsuit against Novopharm to
resolve contract interpretation issues and collect any additional funds
due. In response to Genpharm's suit, Novopharm filed counterclaims against
both Genpharm and the Company claiming damages of up to $60,000,000. The
Company believes the counterclaims against Genpharm and the Company are
without merit and will vigorously defend its position.
O. Fair Value of Financial Instruments
The carrying values of cash and cash equivalents, approximate fair value
due to the short-term maturity of these instruments. Marketable securities
are recorded at fair value based on quoted market prices. The carrying
value of other financial instruments approximates their fair value based on
other appropriate valuation techniques.
P. Stock Option Plans
On January 23, 1997, the Board of Directors adopted the "Mylan
Laboratories Inc. 1997 Incentive Stock Option Plan" ("the Plan") which was
approved by the shareholders on July 24, 1997.
Under the Plan the Company may grant up to 10,000,000 shares of its commo n
stock to officers, employees and nonemployee consultants and agents as
either incentive stock options or nonqualified stock options. Options,
which may be granted at not less than fair market value on the date of the
grant, may be exercised within ten years from the date of grant.
Nonqualified stock options generally vest on date of grant. Incentive stock
options granted have the following vesting schedule: 25% two years from the
date of grant, 25% at the end of year three and the remaining 50% at the
end of year four. As of March 31, 1999, 8,625,000 shares are available for
future grants.
On June 23, 1992, the Board of Directors adopted the "1992
Nonemployee Director Stock Option Plan" ("the Directors' Plan") which was
approved by the shareholders on April 7, 1993. A total of 600,000 shares of
the Company's common stock are reserved for issuance upon exercise of stock
options which may be granted at not less than fair market value on the date
of grant. Options may be exercised within ten years from the date of grant.
As of March 31, 1999, 354,000 shares have been granted pursuant to the
Directors' Plan.
-43-
<PAGE>
Notes to Consolidated Financial Statements
Mylan Laboratories Inc.
Additional stock options are outstanding from the recently expired
1986 Incentive Stock Option Plan and other plans acquired through
acquisitions.
A summary of the activity resulting from all plans is as follows:
Weighted average
Number of shares exercise
under option price per share
Outstanding as of April 1, 1996 2,720,014 $11.87
Options granted 217,000 14.75
Options exercised (290,167) 11.05
Options cancelled (75,970) 15.70
---------- ------
Outstanding as of March 31, 1997 2,570,877 $12.10
Options granted 1,322,000 17.08
Options exercised (235,216) 11.09
Options cancelled (41,175) 14.17
---------- ------
Outstanding as of March 31, 1998 3,616,486 $13.96
Options acquired - Penederm 877,367 15.30
Options granted 186,500 19.74
Options exercised (1,013,313) 12.16
Options cancelled (117,886) 16.96
---------- ------
Outstanding as of March 31, 1999 3,549,154 $15.11
Options outstanding Options exercisable
------------------- -------------------
Weighted
average Weighted Weighted
Range of remaining average average
exercise Number contractual exercise Number exercise
price outstanding life price exercisable price
per share as of 3/31/99 (years) per share as of 3/31/99 per share
-------------------------------------------------------------------------
$ .81-$11.58 391,045 3.57 $7.19 391,045 $ 7.19
$12.00-$12.00 1,023,953 3.23 $12.00 1,023,953 $12.00
$12.32-$16.36 260,228 7.25 $14.66 146,228 $14.58
$16.69-$16.69 763,000 8.32 $16.69 326,000 $16.69
$16.73-$30.15 1,110,928 8.25 $19.60 778,678 $19.23
------------------------------------------------------------------------
$ .81-$30.15 3,549,154 6.25 $15.11 2,665,904 $14.12
At March 31, 1999, options were exercisable for 2,665,904 shares at
a weighted average exercise price of $14.12 per share. The corresponding
amounts were 2,557,856 shares at $13.20 per share at March 31, 1998 and
1,831,061 shares at $11.06 per share at March 31, 1997.
In accordance with the provisions of Statement of Financial
Accounting Standards No. 123 "Accounting for Stock-Based Compensation"
("SFAS No. 123"), the Company will continue to apply the provisions of
Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to
Employees" and, accordingly, does not recognize compensation costs for its
existing stock option plans. If the Company had elected to recognize
compensation costs based on the alternative fair value method prescribed by
SFAS No. 123, net earnings and earnings per share (on both a basic and
diluted basis) would have been reduced by $1,613,000, or $.01 per share,
$6,489,000, or $.04 per share and $1,174,000, or $.01 per share for the
years ended March 31, 1999, 1998 and 1997. These calculations only take
into account options issued since April 1, 1995.
-44-
<PAGE>
Notes to Consolidated Financial Statements
Mylan Laboratories Inc.
The weighted average fair value of options granted during the years
ended March 31, 1999, 1998 and 1997 was $9.37, $6.47, and $6.15. The fair
value was estimated using the Black-Scholes option pricing model based on
the following assumptions:
March 31, 1999 1998 1997
Volatility 42% 35% 35%
Risk-free interest rate 5.0% 6.07% 6.73%
Dividend yield 1.0% 1.0% 1.1%
Expected term of options (in years) 5.2 5.4 6.1
Q. Employee Benefits
The Company maintains profit sharing and/or 401(k) retirement plans
covering essentially all of its employees.
Contributions to the profit sharing plans are made at the discretion
of the Board of Directors. Contributions to the 401(k) plans are based upon
employee contributions or service hours. Total contributions to all plans
for the years ended March 31, 1999, 1998 and 1997 were $4,776,000,
$3,889,000 and $3,620,000 respectively.
In fiscal 1999, the Company adopted a plan covering substantially
all its employees to provide for limited reimbursement of supplemental
postretirement medical coverage. The plan provides benefits to employees
retiring after April 5, 1998, who meet minimum age and service
requirements. The Company has provided for the costs of these benefits,
which are not material. The future obligation related to these benefits is
insignificant.
R. Segment Reporting
Effective April 1, 1998, the Company adopted Statement of Financial
Accounting Standards No. 131 "Disclosures about Segments of an Enterprise
and Related Information," which established reporting and disclosure
standards for an enterprise's operating segments. Operating segments are
defined as components of an enterprise for which separate financial
information is available and regularly reviewed by senior management. The
Company has two reportable operating segments, Generic and Branded
Pharmaceuticals, based on differences in products, marketing and regulatory
approval.
Generic pharmaceutical products are off-patented products,
therapeutically equivalent to a branded name product, marketed to
pharmaceutical wholesalers and distributors, drug store chains and public
and governmental agencies by multiple suppliers. These products have been
approved by the FDA through an Abbreviated New Drug Application process.
Branded pharmaceutical products are generally, when new, patent
protected products marketed directly to health care professionals by a
single provider.
These products have been approved by the FDA primarily through a New
Drug Application process.
The accounting policies of the operating segments are the same as
those descibed in note A. In the following table segment revenues represent
sales to unrelated third parties with corresponding corporate wide cost of
sales used to determine segment profits. Segment profits represent earnings
from continuing operations before a provision for income taxes.
-45-
<PAGE>
Notes to Consolidated Financial Statements
Mylan Laboratories Inc.
March 31, (dollars in Corporate/
thousands) Generic Branded Other Consolidated
Total revenues 1999 $638,122 $83,001 - 721,123
1998 501,320 54,103 - 555,423
1997 381,495 58,697 - 440,192
----------------------------------------------------------------------
Segment profit (1) 1999 228,529 14,941 (51,176) 192,294
1998 145,618 6,728 (3,957) 148,389
1997 74,264 11,718 1,213 87,195
----------------------------------------------------------------------
Segment assets (2) 1999 396,293 257,860 552,508 1,206,661
1998 398,189 126,878 322,686 847,753
1997 318,367 129,796 329,417 777,580
----------------------------------------------------------------------
Property, plant and
equipment additions 1999 11,646 3,991 1,099 16,736
1998 24,843 3,925 85 28,853
1997 25,904 828 122 26,854
----------------------------------------------------------------------
Deprecation and
amortization (1)&(2) 1999 11,452 10,246 5,213 26,911
1998 10,950 8,084 2,674 21,708
1997 9,013 5,717 2,617 17,347
----------------------------------------------------------------------
(1) Corporate and Other Segment Profit includes consolidated
non-operating income less corporate expenses including, legal expenditures,
IPR&D and goodwill amortization.
(2) Generic and Branded Segment Assets include property, plant and
equipment, trade accounts receivable, inventory and intangible assets other
than goodwill. Corporate and Other Segment Assets includes consolidated
cash and cash equivalents, marketable securities,the Company's investment
in Somerset and other assets, goodwill and all income tax related assets.
S. Contingencies
The Company is involved in various legal proceedings that are considered
normal to its business. The majority of these proceedings involve
intellectual property rights related to products under development and
prior to FDA approval. These proceedings are initiated by branded
pharmaceutical companies and often result in delaying the introduction of
generic products. As more of these suits have been initiated against the
Company, the cost to defend these suits in outside legal fees and internal
resource commitments has risen dramatically. While it is not feasible to
predict the ultimate outcome of such proceedings, it is the opinion of
management that the ultimate outcome will not have a material adverse
effect on the Company's operations or its financial position.
In August 1997, Key Pharmaceuticals, Inc. filed suit against the
Company and certain subsidiaries claiming patent infringement relating to
the marketing of its Nitroglycerin Transdermal System. The relief sought
included a preliminary and permanent injunction, treble damages along with
interest and attorneys fees and expenses. All claims and counterclaims were
dismissed pursuant to a settlement between the companies. The Company
continues to manufacture and market its Nitroglycerin Transdermal System in
accordance with the settlement.
A subsidiary of the Company is involved in a dispute relating to a
license and supply contract for Nitroglycerin Transdermal Patches which
both parties claim has been breached by the other. The other company seeks
damages in excess of $20 million. The dispute is subject to binding
arbitration before a three member panel which commenced in March 1999 and
is scheduled to continue in June 1999. Although the Company believes that
the complaint against it is without merit, there can be no assurance that
the Company will prevail in this matter.
In addition to the above, on December 22, 1998, the Federal Trade
Commission ("FTC") filed suit in federal district court for the District of
Columbia against the Company. The FTC alleges that the Company violated
Section 5(a) of the Federal Trade Commission Act (the "FTC Act") with
respect
-46-
<PAGE>
Notes to Consolidated Financial Statements
Mylan Laboratories Inc.
to two generic drugs manufactured and sold by the Company (Lorazepam and
Clorazepate). Specifically, the FTC's complaint alleges the Company engaged
in restraint of trade, monopolization, attempted monopolization, and
conspiracy to monopolize, arising out of certain agreements involving the
supply of raw materials used to manufacture these drugs. The FTC also sued
in the same case the foreign supplier of the raw materials, the supplier's
parent company and its United States distributor. Under the terms of the
agreements related to these raw materials, the Company has agreed to
indemnify these parties. The relief sought includes an injunction barring
the Company from engaging in conduct that violates Section 5(a) of the FTC
Act, rescission of certain agreements and disgorgement in excess of $120
million.
In a parallel case also filed on the same day, Attorneys General for
ten states, Connecticut, Florida, Illinois, Minnesota, New York, North
Carolina, Ohio, Pennsylvania, Virginia and Wisconsin (the "States"), joined
together to file a single lawsuit against the Company in the same court.
The complaint filed by the States asserts claims pursuant to Section 1 and
2 of the federal Sherman Act against the same parties as those named in the
FTC suit and one other distributor not named by the FTC. These claims are
analogous to the claims brought by the FTC under Section 5(a) of the FTC
Act, and are based on similar factual allegations. The States' complaint
also alleges violations of the respective states' competition and consumer
protection laws. The States further allege a per se violation of Section 1
of the Sherman Act with respect to the pricing of raw material used in the
manufacture of Lorazepam (an allegation not made by the FTC). Without
specifying a dollar amount, the States seek relief similar to that sought
by the FTC, treble damages and attorneys' fees. The complaint was amended
in February 1999 to include 22 additional states as plaintiffs. In
addition, the State of Maryland has
filed a similar but independent suit.
The Company is aware of more than 20 class actions filed by private
parties in various state and federal courts involving the same conduct
alleged in the complaints brought by the FTC and the States, as well as
alleged violations of state consumer protection laws. The lawsuits seek
unspecified amounts of damages.
In addition, on January 11, 1999, a class action suit was filed in
federal district court for the Western District of Pennsylvania alleging
violations of federal secu-rities laws by the Company and certain directors
and officers of the Company.
The suit alleges that the Company failed to disclose monopolization of
certain raw materials used to manufacture Lorazepam and Clorazepate
pursuant to Sections 10(b) and 20 of the Securities and Exchange Act of
1934 and Rule 10 b-5 of the Securities and Exchange Commission. The alleged
class period is from February 17, 1998 to December 5, 1998. Without
specifying a dollar amount, the suit seeks compensatory damages.
The Company has filed motions to dismiss the FTC and State
Attorneys' General cases as well as the federal securities case filed in
U.S. Federal District Court for the Western District of Pennsylvania. In
addition, two of these private actions have been dismissed.
The Company believes that it has meritorious defenses to the claims
in all remaining suits and intends to vigorously defend them. Although the
Company believes it has meritorious defenses to the claims, an adverse
result in these suits could have a material adverse effect on the Company's
financial position and results of its operations.
The Company is currently involved in negotiations with a State
agency concerning certain contract pricing matters. Management believes the
resolution of this matter will not have a material adverse effect on the
Company's operations or its financial position.
Since 1994, the Company had been providing funding to VivoRx Inc.
("VivoRx"), a California based research and development company which is
pursuing diabetes related research. The Company suspended cash funding to
VivoRx for periods after March 31, 1998, pending resolution of accounting
and
-47-
<PAGE>
Notes to Consolidated Financial Statements
Mylan Laboratories Inc.
other issues raised by the Company. In June, 1998, the Company commenced
litigation against VivoRx, certain VivoRx officers and directors and
certain companies owned or controlled by those officers and directors. In
March, 1999, VivoRx filed counterclaims against the Company seeking
compensatory and punitive damages in an unspecified amount. Upon motions
made by the Company, it was ordered that certain of the disputes relating
to the exclusive licensing agreement between the parties were to be decided
in a separate arbitration proceeding. This proceeding was concluded in
April, 1999 and on May 18, 1999, the Company received notice of the
arbitrator's decision.
Under the terms of the arbitration award, the Company must fund
approximately $10 million for research and development performed by VivoRx
subsequent to March 31, 1998. In turn, the Company was permitted, at its
election, either to (1) continue in effect and continue funding the
exclusive licensing agreement between the parties, or (2) terminate its
rights under the agreement and receive payment from VivoRx of approximately
$18 million, representing 50% of the amounts it has funded for research and
development to date
(including the $10 million discussed above). The Company elected to
terminate the agreement and, therefore, VivoRx must pay to it the amounts
due, plus interest, in five annual installments commencing October 1, 2000.
This obligation will be secured by a security interest in VivoRx's
diabetes-related U.S. patents.
As a result of this award, the Company has recorded the effects of
the $10 million funding obligation discussed above in its fiscal 1999
financial statements as research and development expense. The $18 million
required to be paid by VivoRx will be recognized as income when realized.
Various disputes between the Company and VivoRx and other parties
remain the subject of on-going litigation. While it is not feasible to
predict the ultimate outcome of this litigation, it is the opinion of
management that the ultimate outcome will not have a material adverse
effect on the Company's operations or financial position.
- - --------------------------------------------------------------------------------
Independent Auditors' Report
Mylan Laboratories Inc.
Board of Directors and Shareholders
Mylan Laboratories Inc.
Pittsburgh, Pennsylvania
We have audited the accompanying consolidated balance sheets of Mylan
Laboratories Inc. and subsidiaries as of March 31, 1999 and 1998, and the
related consolidated statements of earnings, shareholders' equity and
comprehensive earnings, and cash flows for each of the three years in the period
ended March 31, 1999, appearing on pages 30 through 48. These financial
statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, such consolidated financial statements present fairly,
in all material respects, the financial position of Mylan Laboratories Inc. and
subsidiaries as of March 31, 1999 and 1998, and the results of their operations
and their cash flows for each of the three years in the period ended March 31,
1999, in conformity with generally accepted accounting principles.
/s/Deloitte & Touche LLP
Deloitte & Touche LLP
Pittsburgh, Pennsylvania
May 14, 1999 (May 18, 1999 as to note S)
-48-
<PAGE>
Market Information
Mylan Laboratories Inc.
Quarterly Financial Data
(Amounts in thousands 1st 2nd 3rd 4th
except per share amounts) Quarter Quarter Quarter Quarter Year
Fiscal 1999
Total revenues $166,718 $177,592 $186,195 $190,618 $721,123
Gross profit 85,154 92,044 99,716 107,363 384,277
Net earnings 34,182 37,215 8,154 35,858 115,409
Earnings per share-basic .28 .30 .06 .28 .92
Earnings per share-diluted .28 .30 .06 .27 .91
Fiscal 1998
Total revenues $109,188 $153,955 $129,517 $162,763 $555,423
Gross profit 47,809 55,932 54,440 82,130 240,311
Net earnings 16,598 30,390 21,983 31,806 100,777
Earnings per share-basic .14 .25 .18 .26 .83
Earnings per share-diluted .13 .25 .18 .26 .82
Total revenues for fiscal 1998 include $26,822,000 recognized in
the 2nd quarter relating to the Genpharm License Agreement (see note N to
the consolidated financial statements).
Market Prices
1st 2nd 3rd 4th
Quarter Quarter Quarter Quarter
Fiscal 1999
High 32 3\4 35 1\8 35 15\16 32
Low 22 1\16 22 1\8 24 5\16 26 1\4
Fiscal 1998
High 16 7\8 24 3\4 25 1\4 24 5\16
Low 11 1\8 14 5\8 17 7\16 17 1\16
New York Stock Exchange Symbol: MYL
On April 30, 1999 the Company had approximately 74,842 shareholders.
Split Date
Amount Split Price Presplit Price
July 20, 1979 5/4 10 3\4 13 1\2
November 13, 1981 2/1 13 1\2 27 1\8
June 30, 1983 2/1 16 1\4 32 1\2
March 1, 1984 3/2 14 21
July 31, 1984 3/2 19 7\8 29 3\4
February 15, 1985 2/1 17 7\8 35 3\4
August 1, 1986 3/2 14 21
August 1, 1992 2/1 21 3\4 43 1\2
August 15, 1995 3/2 21 31 1\2
-49-
EXHIBIT 21
Subsidiaries
Name State of Incorporation
- - ---- ----------------------
Milan Holding, Inc. Delaware
Mylan Inc. Delaware
Mylan Pharmaceuticals Inc. West Virginia
Mylan Caribe Inc. Vermont
Bertek Pharmaceuticals, Inc. Texas
Mylan Technologies, Inc. West Virginia
American Triumvirate Insurance Company Vermont
Roderick Corporation Delaware
UDL Laboratories, Inc. Illinois
Penederm Inc. California
INDEPENDENT AUDITORS' CONSENT
We consent to the incorporation by reference in Registration Statements Nos.
333-65329, 333-65327, 333-35887, 333-43081, 33-65916, 33-65918 of Mylan
Laboratories Inc. on Form S-8 of our report dated May 14, 1999 (May 18, 1999 as
to Note S), incorporated by reference in this Annual Report on Form 10-K of
Mylan Laboratories Inc. for the year ended March 31, 1999.
/s/ Deloitte & Touche LLP
Deloitte & Touche LLP
Pittsburgh, Pennsylvania
June 24, 1999
<PAGE>
INDEPENDENT AUDITORS' CONSENT
We consent to the incorporation by reference in Registration Statement Nos.
333-65329, 333-65327, 333-35887, 333-43081, 33-65916, 33-65918 of Mylan
Laboratories Inc. on Form S-8 of our report dated January 29, 1999, relating to
the consolidated financial statements of Somerset Pharmaceuticals, Inc. and
subsidiaries for each of the three years in the period ended December 31, 1998,
included in the Annual Report on Form 10-K of Mylan Laboratories Inc. for the
year ended March 31, 1999.
/s/ Deloitte & Touche LLP
Deloitte & Touche LLP
Pittsburgh, Pennsylvania
June 24, 1999
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
Exhibit 27
Financial Data Schedule
Mylan Laboratories Inc. and Subsidiaries
Article 5 of Regulation S-X
The schedule contains summary financial information extracted from the
Consolidated Balance Sheets at March 31, 1999 and the Consolidated Statement of
Earnings for the twelve months ended March 31, 1999 and is qualified in its
entirety by reference to such financial statements.
</LEGEND>
<CIK> 0000069499
<NAME> Exhibit 27
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 12-MOS
<FISCAL-YEAR-END> MAR-31-1998
<PERIOD-END> MAR-31-1998
<CASH> 189,849
<SECURITIES> 69,872
<RECEIVABLES> 192,480
<ALLOWANCES> 43,584
<INVENTORY> 136,493
<CURRENT-ASSETS> 582,959
<PP&E> 244,793
<DEPRECIATION> 90,157
<TOTAL-ASSETS> 1,206,661
<CURRENT-LIABILITIES> 96,361
<BONDS> 30,305
0
0
<COMMON> 64,984
<OTHER-SE> 994,921
<TOTAL-LIABILITY-AND-EQUITY> 1,206,661
<SALES> 721,123
<TOTAL-REVENUES> 721,123
<CGS> 336,846
<TOTAL-COSTS> 336,846
<OTHER-EXPENSES> 215,807
<LOSS-PROVISION> 872
<INTEREST-EXPENSE> 1,793
<INCOME-PRETAX> 192,294
<INCOME-TAX> 76,885
<INCOME-CONTINUING> 115,409
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 115,409
<EPS-BASIC> 0.92
<EPS-DILUTED> 0.91
</TABLE>
SOMERSET PHARMACEUTICALS, INC. AND SUBSIDIARIES
Consolidated Financial Statements for the
Years Ended December 31, 1998, 1997 and 1996, and
Independent Auditors' Report
<PAGE>
INDEPENDENT AUDITORS' REPORT
To the Board of Directors of
Somerset Pharmaceuticals, Inc.:
We have audited the accompanying consolidated balance sheets of Somerset
Pharmaceuticals, Inc. and subsidiaries as of December 31, 1998 and 1997, and the
related consolidated statements of income, stockholders' equity, and cash flows
for each of the three years in the period ended December 31, 1998. These
financial statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, such consolidated financial statements present fairly, in all
material respects, the financial position of Somerset Pharmaceuticals, Inc. and
subsidiaries as of December 31, 1998 and 1997, and the results of their
operations and their cash flows for each of the three years in the period ended
December 31, 1998 in conformity with generally accepted accounting principles.
/s/ Deloitte & Touche LLP
Deloitte & Touche LLP
Pittsburgh, Pennsylvania
January 29, 1999
<PAGE>
SOMERSET PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 1998 AND 1997
- - --------------------------------------------------------------------------------
ASSETS 1998 1997
CURRENT ASSETS:
Cash and cash equivalents $ 18,672,000 $ 32,141,000
Investment securities 41,412,000 15,963,000
Accounts receivable (net of
allowance for doubtful accounts
of $206,000 and $250,000, respectively) 6,085,000 3,526,000
Inventories 2,350,000 1,077,000
Prepaid expenses and other current assets 2,410,000 1,266,000
----------- -----------
Total current assets 70,929,000 53,973,000
PROPERTY AND EQUIPMENT - Net 514,000 752,000
INTANGIBLE ASSETS - Net 868,000 1,066,000
OTHER ASSETS 658,000 1,648,000
------------ ------------
$ 72,969,000 $ 57,439,000
============ ============
LIABILITIES AND STOCKHOLDERS' EQUITY 1998 1997
CURRENT LIABILITIES:
Accounts payable $ 1,281,000 $ 516,000
Royalty payable 799,000 1,172,000
Medicaid payable 578,000 687,000
Other accrued expenses 587,000 853,000
Accrued research and development 2,924,000 4,394,000
Income taxes payable 8,280,000 5,099,000
Accrued sales returns 800,000 906,000
Accrued compensation 740,000 600,000
Amounts due to related parties 595,000 1,433,000
----------- ----------
Total current liabilities 16,584,000 15,660,000
STOCKHOLDERS' EQUITY:
Common stock, $.01 par value; 13,719
shares authorized, 11,297 shares issued - -
Retained earnings 56,837,000 42,231,000
Less treasury stock, 644 shares at cost (452,000) (452,000)
------------ ------------
Total stockholders' equity 56,385,000 41,779,000
------------ ------------
$ 72,969,000 $ 57,439,000
============ ============
See notes to consolidated financial statements.
-2-
<PAGE>
SOMERSET PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
YEARS ENDED DECEMBER 31, 1998, 1997 AND 1996
- - --------------------------------------------------------------------------------
1998 1997 1996
NET SALES $ 43,557,000 $ 66,956,000 $ 101,512,000
------------ ------------ -------------
COSTS AND EXPENSES:
Cost of sales 4,623,000 6,622,000 12,672,000
Marketing 4,587,000 5,757,000 6,263,000
Research and development 7,269,000 13,073,000 20,118,000
Administrative 6,449,000 7,338,000 9,574,000
------------ ------------ ------------
22,928,000 32,790,000 48,627,000
------------ ------------ ------------
20,629,000 34,166,000 52,885,000
OTHER INCOME - Net 3,612,000 2,735,000 1,732,000
------------ ------------ ------------
INCOME BEFORE INCOME TAXES 24,241,000 36,901,000 54,617,000
PROVISION FOR INCOME TAXES 9,635,000 12,924,000 18,815,000
------------ ------------ ------------
NET INCOME $ 14,606,000 $ 23,977,000 $ 35,802,000
============ ============ ============
See notes to consolidated financial statements.
-3-
<PAGE>
<TABLE>
<CAPTION>
SOMERSET PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
YEARS ENDED DECEMBER 31, 1998, 1997 AND 1996
<S> <C> <C> <C> <C> <C> <C>
- - ----------------------------------------------------------------------------------------------------------
Common Stock Treasury Stock Retained Stockholders'
----------------------- --------------------------------------------------
Shares Amount Shares Amount Earnings Equity
BALANCE, DECEMBER 31, 1995 11,297 $ - 644 $ (452,000) $ 34,452,000 $ 34,000,000
------ ---------- ----- ---------- ------------ ------------
Net income - - - - 35,802,000 35,802,000
Dividends - - - - (36,000,000) (36,000,000)
------ ---------- ----- ---------- ------------ ------------
BALANCE, DECEMBER 31, 1996 11,297 - 644 (452,000) 34,254,000 33,802,000
Net income - - - - 23,977,000 23,977,000
Dividends - - - - (16,000,000) (16,000,000)
------ ---------- ----- ---------- ------------ ------------
BALANCE, DECEMBER 31, 1997 11,297 - 644 (452,000) 42,231,000 41,779,000
Net income - - - - 14,606,000 14,606,000
------ ---------- ----- ---------- ------------ ------------
BALANCE, DECEMBER 31, 1998 11,297 $ - 644 $ (452,000) $ 56,837,000 $ 56,385,000
====== ========== ===== ========== ============ ============
See notes to consolidated financial statements.
-4-
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
SOMERSET PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 1998, 1997 AND 1996
<S> <C> <C> <C>
- - ----------------------------------------------------------------------------------------------------
1998 1997 1996
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income $ 14,606,000 $ 23,977,000 $ 35,802,000
Adjustments to reconcile net income to net cash
provided by operating activities:
Depreciation and amortization 429,000 952,000 1,048,000
Deferred tax expense (benefit) 232,000 (8,000) (736,000)
Loss on sale of property and equipment 5,000 422,000 -
Deferred revenue - - (63,000)
Changes in operating assets and liabilities:
Accounts receivable (2,559,000) 2,646,000 7,703,000
Inventories (1,273,000) 627,000 4,847,000
Prepaid expenses and other current assets (1,144,000) 2,415,000 (1,438,000)
Accounts payable 765,000 (135,000) (861,000)
Royalty payable (373,000) (454,000) (3,050,000)
Medicaid payable (109,000) - -
Accrued research and development (1,470,000) (184,000) 2,657,000
Other accrued expenses (232,000) (1,521,000) 2,084,000
Income taxes payable 3,181,000 (933,000) 1,642,000
Amounts due to related parties (838,000) (188,000) (454,000)
----------- ----------- -----------
Net cash provided by operating activities 11,220,000 27,616,000 49,181,000
----------- ----------- -----------
CASH FLOWS FROM INVESTING ACTIVITIES:
Net increase in investment securities (25,449,000) (14,955,000) (828,000)
Purchases of property and equipment (12,000) (42,000) (251,000)
Proceeds from sale of property and equipment 14,000 2,000,000 -
Decrease in other assets 758,000 45,000 60,000
----------- ----------- -----------
Net cash used in investing activities (24,689,000) (12,952,000) (1,019,000)
----------- ----------- -----------
-5- (Continued)
</TABLE>
<PAGE>
SOMERSET PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 1998, 1997 AND 1996
- - ------------------------------------------------------------------------------
1998 1997 1996
CASH FLOWS FROM FINANCING ACTIVITIES -
Dividends paid on common stock $ - $ (16,000,000) $(36,000,000)
------------ ------------- ------------
Cash used in financing activities - (16,000,000) (36,000,000)
------------ ------------- ------------
NET (DECREASE) INCREASE IN CASH AND
CASH EQUIVALENTS (13,469,000) (1,336,000) 12,162,000
CASH AND CASH EQUIVALENTS,
BEGINNING OF YEAR 32,141,000 33,477,000 21,315,000
------------ ------------- ------------
CASH AND CASH EQUIVALENTS,
END OF YEAR $ 18,672,000 $ 32,141,000 $ 33,477,000
============ ============ ============
SUPPLEMENTAL DISCLOSURES OF
CASH FLOW INFORMATION -
Cash paid during the year for
income taxes $ 7,762,000 $ 12,092,000 $ 20,409,000
============ ============ ============
See notes to consolidated financial statements.
-6-
<PAGE>
SOMERSET PHARMACEUTICALS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
YEARS ENDED DECEMBER 31, 1998, 1997 AND 1996
1. PRINCIPLES OF CONSOLIDATION AND OPERATIONS
The consolidated financial statements include the accounts of Somerset
Pharmaceuticals, Inc. (the "Company") and its wholly owned subsidiaries,
Somerset Pharmaceuticals Holding Company and Somerset Caribe, Inc. The
Company is jointly owned by Mylan Laboratories, Inc. and Watson
Pharmaceuticals, Inc. ("Watson"), with each owning 50% of the outstanding
common stock of the Company. All significant intercompany accounts and
transactions have been eliminated in consolidation. The Company, incorporated
in February 1986, is engaged in the development, testing and marketing of
drugs to be used in the treatment of various human disorders. Currently, the
Company manufactures (at its facility in Puerto Rico), markets and sells
Eldepryl, which is used as a treatment for Parkinson's Disease. The Company
had exclusivity relating to the chemical compound Eldepryl for use as a
treatment for late stage Parkinson's Disease through June of 1996. In May
1996, the Company received approval from the Food and Drug Administration for
Eldepryl capsules and withdrew the tablet form from the marketplace.
Competitors entered the marketplace with a generic version of the tablet in
August 1996. The loss of exclusivity and the introduction of competitive
products has had and could continue to have a material impact on the
Company's future operating results.
The Company is party to an exclusive 14-year agreement (through November 22,
2003) with Chinoin Pharmaceutical Company ("Chinoin") of Budapest, Hungary
under which Eldepryl and other new potential drugs resulting from Chinoin
research are made available for licensing by the Company. The license
agreement required the Company to pay royalties equal to 7% of net sales of
Eldepryl including sub-license revenues. During 1996, the license agreement
was amended to reduce the Eldepryl royalties to 3.5% of net sales subsequent
to May 31, 1996. The Company incurred royalty expense of approximately
$1,730,000, $2,716,000, and $5,917,000 for the years ended December 31, 1998,
1997 and 1996, respectively. The license agreement also requires the Company
to purchase the main raw material used in the manufacture of Eldepryl from
Chinoin through June 1999.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
a. Cash and Cash Equivalents - The Company generally considers debt
instruments purchased with a maturity of three months or less and
investments in money market accounts to be cash equivalents.
b. Investment Securities - The Company accounts for investment securities in
accordance with Statement of Financial Accounting Standards ("SFAS") No.
115, "Accounting for Certain Investments in Debt and Equity Securities."
At December 31, 1998 and 1997, the investment securities were
available-for-sale, and there were no material unrealized gains or losses.
Proceeds from sales and maturities of investments were $116,712,000 and
$44,973,000, in 1998 and 1997, respectively. In 1998 there were $1,356,000
of realized gains and $23,400 of realized losses. There were no material
realized gains or losses in 1997. There were no sales or maturities of
investments in 1996. The gain or loss on sale is based on the specific
identification method.
c. Inventories - Inventories are stated at the lower-of-cost or market, with
cost determined on a first-in, first-out basis.
-7-
<PAGE>
d. Property and Equipment - Property and equipment are stated at cost.
Depreciation is provided over the estimated useful lives of the assets by
the straight-line method. Estimated useful lives are five to seven years.
e. Intangible Assets - Intangible assets are amortized on a straight-line
basis over 14 years.
f. Research and Development - Research and development costs are expensed as
incurred.
g. Concentration of Credit Risk - The Company's product is sold throughout
the United States principally to distributors and wholesalers in the
pharmaceutical industry. The Company performs ongoing credit evaluation of
its customers' financial condition and generally requires no collateral
from its customers.
h. Use of Estimates in the Preparation of Financial Statements - The
preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
the disclosure of contingent assets and liabilities at the date of the
financial statements, as well as the reported amounts of income and
expenses during the reporting period. Actual results could differ from
those estimates.
3. INVENTORIES
Inventories consist of the following at December 31, 1998 and 1997:
1998 1997
Raw material $ 1,853,000 $ 461,000
Work in process - 1,000
Finished goods 497,000 615,000
----------- -----------
Total $ 2,350,000 $ 1,077,000
=========== ===========
4. PROPERTY AND EQUIPMENT
Property and equipment consists of the following at December 31, 1998 and
1997:
1998 1997
Machinery and equipment $ 1,216,000 $ 1,263,000
Furniture and fixtures 90,000 97,000
----------- -----------
1,306,000 1,360,000
Less accumulated depreciation 792,000 608,000
----------- -----------
Property and equipment - net $ 514,000 $ 752,000
=========== ===========
-8-
<PAGE>
5. SUB-LICENSE OF RIGHTS
On February 9, 1988, the Company granted a sub-license to its exclusive right
and license to use its technology to Draxis Health Inc. (formerly Deprenyl
Research Limited) to commercialize certain drugs in Canada for 15 years. The
Company receives a royalty of 11% of Draxis Health Inc.'s net sales over the
license period.
Royalty income, net of related royalty expense payable to Chinoin, included
in other income for the years ended December 31, 1998, 1997 and 1996 was
approximately $97,000, $261,000 and $175,000, respectively.
6. INTANGIBLE ASSETS
Intangible assets primarily represent the cost of a modification to the terms
of the Chinoin Agreement, less accumulated amortization of $1,832,000, and
$1,639,000 at December 31, 1998 and 1997, respectively.
7. CO-PROMOTIONAL AGREEMENT
In 1990, the Company entered into an agreement with Sandoz Pharmaceuticals
Corporation ("Sandoz") to co-promote the product Eldepryl. The agreement
required Sandoz, among other things, to expend, at a minimum, a predetermined
amount for advertising during each year of the agreement. In December 1994,
the Company amended its co-promotional agreement with Sandoz. The amended
agreement eliminated certain residual period payments to Sandoz, shortened
the term to March 31, 1996, eliminated certain sales force detail
requirements and required certain payments to be made to the Company if a
predetermined level of sales was not achieved.
The Company had previously entered into an agreement with CoCensys, Inc.
("CoCensys") for the promotion of Elderpryl. The agreement was effective
January 1, 1996 and had an initial term of two years. Under the terms of the
original agreement, the Company would have compensated CoCensys, based on a
predetermined formula that considered both the number of new prescriptions
written and the net sales dollars achieved in each quarter. During 1996 and
1997, the agreement was modified with respect to term, new prescriptions and
detail calls. During 1997, CoCensys was acquired by Watson. The Company paid
Watson $4.7 million for the promotion and marketing of Elderpryl during 1998.
During 1997 and 1996, the Company expensed $3,800,000 and $1,230,000,
respectively, pursuant to these agreements with CoCensys. Additionally,
certain co-promotional fees paid by Sandoz at the commencement of the 1990
agreement were recognized ratably by the Company during the term of the
agreement (six years, expiring on March 31, 1996), and certain costs
associated with the procurement, negotiating and execution of the agreement
by the owners of the Company were incurred by the Company in approximately
the same amount.
8. OTHER INCOME
In November 1994, the Company prevailed in litigation it brought against
foreign defendants who were selling and marketing chemical compounds similar
to Eldepryl without FDA approval. In late 1997, a final judgment was rendered
by the United States Federal District Court. In November 1997, the Company
received and recorded as other income approximately $1,225,000 for settlement
of the litigation and reimbursement of related costs.
-9-
<PAGE>
During November 1997, the Company sold its research and development facility
and related equipment with a net book value of approximately $3,422,000 for
$3,000,000. The resulting loss of $422,000 is recorded as a reduction in
other income. The Company financed in the form of a note $1,000,000 of the
sales price. The note receivable is collateralized by the facility and will
be collected in 60 monthly installments bearing interest at 8%. Current and
non-current portions are included with prepaid expenses and other current
assets and other assets, respectively, in the consolidated balance sheet at
December 31, 1997. In September 1998, the total outstanding portion of this
note receivable was received in full.
9. INCOME TAXES
The income tax provision consists of the following for the years ended
December 31, 1998, 1997 and 1996:
1998 1997 1996
Current tax expense:
Federal $ 7,800,000 $10,283,000 $15,257,000
State 1,603,000 2,549,000 4,194,000
Foreign - 100,000 100,000
----------- ----------- -----------
9,403,000 12,932,000 19,551,000
----------- ----------- -----------
Deferred tax expense (benefit):
Federal 211,000 (7,000) (669,000)
State 21,000 (1,000) (67,000)
----------- ----------- -----------
232,000 (8,000) (736,000)
----------- ----------- -----------
Total provision for income taxes $ 9,635,000 $12,924,000 $18,815,000
=========== =========== ===========
Deferred income taxes reflect the net tax effects of temporary differences
between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes. The tax
effects of significant items comprising the Company's deferred taxes (which
are included in "Other Assets" in the consolidated balance sheet) at December
31, 1998 and 1997 are as follows:
1998 1997
Deferred tax assets:
Chargeback and rebate allowances $ 510,000 $ 593,000
Deferred compensation 229,000 223,000
Inventory valuation allowance - 243,000
Other 100,000 95,000
--------- ---------
839,000 1,154,000
Deferred tax liabilities - different methods of accounting
between financial and income tax reporting for depreciation
and amortization 243,000 326,000
--------- ---------
Net deferred tax assets $ 596,000 $ 828,000
========= =========
-10-
<PAGE>
The statutory federal income tax rate is reconciled to the effective tax rate
as follows for the years ended December 31, 1998, 1997 and 1996:
1998 1997 1996
Tax at statutory rate 35.0 % 35.0 % 35.0 %
State income tax (net of federal benefit) 3.6 3.8 3.6
Tax credits (6.2) (7.9) (9.5)
Tollgate tax 3.1 3.4 4.0
Other 4.2 0.7 1.3
---- ---- ----
Effective tax rate 39.7 % 35.0 % 34.4 %
==== ==== ====
Tax credits result principally from operations in Puerto Rico.
See Note 13.
10.RELATED PARTY TRANSACTIONS
The Company incurs expenses for ongoing management services and over a
six-year period (which ended March 31, 1996) for specific services related to
the procurement, negotiation and execution of the original co-promotion
agreement by one of the owners of the Company. The Company also has other
transactions with one or both of its owners as detailed below for the years
ended December 31, 1998, 1997 and 1996:
1998 1997 1996
Management fees $ 2,167,000 $ 3,348,000 $ 5,076,000
Marketing and advertising 4,714,000 775,000 -
Research and development 232,000 90,000 1,250,000
Inventory handling and distribution fees 524,000 465,000 519,000
Rent - equipment and facilities 14,000 640,000 1,217,000
11.SIGNIFICANT CUSTOMERS
The Company had sales to certain customers which individually exceeded 10% of
sales. In 1998 sales to three major customers were $8,983,000, $8,013,000 and
$6,953,000, respectively. In 1997 sales to five major customers were
$15,878,000, $13,498,000, $11,427,000, $8,658,000 and $7,746,000,
respectively. In 1996 sales to three major customers were $23,200,000,
$21,259,000 and $18,692,000, respectively.
12.EMPLOYEE BENEFIT PLANS
Effective January 1, 1998, the Company created a new defined contribution
profit sharing plan covering substantially all employees. Contributions are
made at the discretion of the Board of Directors. The defined contribution
profit sharing plan in effect prior to 1998 was terminated as of December 31,
1997. Additionally, during 1994, the Company initiated a deferred
compensation plan for certain key employees which was terminated during 1997.
During 1998, 1997 and 1996, the Company recorded expense of $120,000, $-0-
and $954,000, respectively, under these plans.
-11-
<PAGE>
13.CONTINGENCIES
IRS
In connection with an examination of the Company's Federal tax returns for
the three years ended December 31, 1995, representatives of the Internal
Revenue Service, in June 1997, issued to the Company a report that contains
proposed adjustments to the Company's use of tax credits under Internal
Revenue Code section 936.
Under the proposed adjustments, the Company could be subject to approximately
$14 million of additional income tax and interest charges that have not been
accrued at December 31, 1998.
Management believes that the Company has met all of the requirements to
qualify for the tax credits available under Internal Revenue Code section
936, and intends to vigorously defend its position on this matter.
FoxMeyer
The Company has been named as a defendant in a complaint filed by the trustee
to the bankruptcy estates of FoxMeyer Corporation and its related entities in
the U.S. Bankruptcy Court for the District of Delaware. The complaint alleges
that the Company received preferential payments of approximately $3.4 million
from the bankruptcy estates and seeks reimbursement from the Company of such
amounts. The Company has filed an answer to the complaint denying the
allegations.
In the opinion of management, the outcome of these proceedings should not
have a material adverse effect on the Company's financial position or results
of operations.
* * * * * *
-12-
